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This project investigated the role of miRNA-21 in the macrophage response to 
peritonitis; with the goal of understanding whether the associated mechanism 
has potential benefits in the clinical treatment of peritonitis. A novel therapeutic 
intervention in the treatment of peritonitis could modulate the host immune 
response to decrease an exaggerated pro-inflammatory innate response and 
then prevent or ameliorate the development of sepsis and organ failure. We 
found the following: 
1. MiRNA-21 expression increases in peritoneal macrophages after 
lipopolysaccharide (LPS) stimulation. 
2. Over expression of miRNA-21 decreases TNF-α secretion from 
macrophages after LPS stimulation. Suppression of miRNA-21 expression 




3. Protein targets of miRNA-21 after LPS stimulation were not significantly 
different following suppression of miRNA-21. 
4. NF-κB and ERK signaling was unaffected by suppression of miRNA-21. 
5. MiRNA-21 is beneficial in survival following induction of peritonitis with 
LPS. 
6. MiRNA-21 does not affect survival following induction of peritonitis with 
cecal ligation and puncture. 
 
These findings demonstrate that although miRNA-21 is beneficial in 
modulating the macrophage response to LPS, the effect is buried in the 
multiple pathways activated after the clinically more relevant model of cecal 
ligation and puncture. The improved understanding of the anti-inflammatory 
effects of miRNA-21 in the macrophage response to peritonitis may result in a 
targeted therapy to intervene in clinical peritonitis. 
vii 
 
TABLE OF CONTENTS 
Page 
Acknowledgements ……………………………………………………………. iii 
Abstract …………………………………………………………………………. v 
List of Figures ………………………………………………………………….. x 
 
Chapter 
I. Introduction ………………………………………………………... 1 
II. General Overview ……………………………………..…………… 3 
A. Clinical Importance of Peritonitis ……………………............. 3 
B. Immune Response Overview …………………………………. 5 
C. Macrophages ……………………………………..………..……. 7 
D. MicroRNAs …………………………….…………………………. 10 
E. Models of Peritonitis ……………………………………………. 16 
III. Hypothesis and Experimental Plan …………………….………… 20 
A. Key Objective ……………………………………………………. 20 
B. Hypothesis ……………………………………………...……..... 20 
C. Specific Aims ……………………………………………..…….. 21 
D. Experimental Plan …………………………………………….... 21
viii 
 
E. Methods………………………………………………………….. 22 
i. Mice………………………………………………….…… 22 
ii. Harvest of Peritoneal Cells……………………………. 24 





vi. MiRNA and MessengerRNA Expression…………..... 28 
vii. Cytokine Assays………………………………………… 29 
viii. Protein Isolation…………………………………………. 29 
ix. Western Blot…………………………………………….. 30 
x. MiRNA Transfection…………………………………….. 31 
xi. Phosflow Pathway Analysis…………………………… 32 
xii. Peritonitis Models……………………………………….. 33 
xiii. Statistical Analysis……………………………………… 35 
IV. MiRNA-21 Expression in Peritoneal Macrophages…………….. 36 
A. Introduction………………………………………………………. 36 
B. Results……………………………………………………………. 36 
C. Discussion……………………………………………………….. 44 
V. MiRNA-21 has Anti-Inflammatory Effects in Peritoneal 
Macrophages………………………………………………………… 46 
A. Introduction………………………………………………………. 46 
B. Results……………………………………………………………. 47 
C. Discussion……………………………………………………….. 51 
VI. MiRNA-21 has Anti-Inflammatory Effects in BMM Macrophages 
………………………………………………………………………… 53 
A. Introduction……………………………………………………… 53 
B. Results…………………………………………………………… 54 
C. Discussion………………………………………………………… 60 
VII. MiRNA-21 affects NF-κB and ERK signaling …………………… 64 
ix 
 
A. Introduction………………………………………………………. 64 
B. Results……………………………………………………………. 65 
C. Discussion………………………………………………………… 68 
VIII. Influence of miRNA-21 on Survival in LPS Peritonitis………..... 70 
A. Introduction………………………………………………………. 70 
B. Results……………………………………………………………. 71 
C. Discussion……………………………………………………….. 71 
IX. Influence of miRNA-21 on Survival in Cecal Ligation and Puncture 
Peritonitis………………………………………………………….…. 78 
A. Introduction………………………………………………………. 78 
B. Results……………………………………………………………. 79 
C. Discussion……………………………………………………….. 79 
X. MiRNA-21 Expression in Peritoneal Macrophages following Cecal 
Ligation and Puncture………………………………………………. 88 
A. Introduction………………………………………………………. 88 
B. Results……………………………………………………………. 89 
C. Discussion………………………………………………………… 96 
XI. Conclusions and Overview………………………………………… 98 
References ………………………………………………………………………102 









LIST OF FIGURES 
Figure                Page 
1. Toll-like Receptor-4 signaling…………………………………………. 9 
2. Outline of Study…………………………………………………………. 23 
3. CD11b isolation of Peritoneal Macrophages……………………….. 26  
4. Lipopolysaccharide Peritonitis Survival Curves………………….…. 34  
5. Peritoneal Macrophage MiRNA-21 Expression after  
Lipopolysaccharide……………………………………………………… 37 
6. Peritoneal Macrophage Pro-inflammatory cytokines after 
Lipopolysaccharide……………………………………………………… 39 
7. Peritoneal Macrophage Anti-inflammatory cytokine after 
Lipopolysaccharide……………………………………………………… 40 
8. Peritoneal Macrophage PDCD4 messengerRNA expression after 
Lipopolysaccharide…………………………………………………….. 41 
9. Peritoneal Macrophage Peli1 messengerRNA expression  
after Lipopolysaccharide………………………………………………. 42 




11. MiRNA-21 Expression after transfection…………………………….. 48 
12. Effect of MiRNA-21 on TNF-α..………………………………………... 49 
13. Effect of MiRNA-21 on IL-10…………………………………………… 50 
14. TNF-α in Bone Marrow derived Macrophages………………………. 55 
15. IL-6 in Bone Marrow derived Macrophages…………………………. 56 
16. IL-10 in Bone Marrow derived Macrophages……………………….. 57 
17. PDCD4 in Bone Marrow derived Macrophages…………………….. 58 
18. Peli1 in Bone Marrow derived Macrophages………………………… 59  
19. SPRY 1 and 2 in Bone Marrow derived Macrophages…………….. 61  
20. NF-κB Activation after Lipopolysaccharide in Bone Marrow derived 
Macrophages……………………………………………………………. 66 
21. ERK Activation after Lipopolysaccharide in Bone Marrow derived 
Macrophages……………………………………………………………. 67  
22. Mouse Surface Temperatures after Lipopolysaccharide Peritonitis 
…………………………………………………………………………….. 72 
23. Mouse Weight after Lipopolysaccharide Peritonitis …………….…. 73 
24. Survival after Lipopolysaccharide Peritonitis………………………… 74 
25. Surface Temperature and Weight in mice after Cecal Ligation and 
Puncture………………………………………………………………….. 80 
26. Survival after 20G Cecal Ligation and Puncture……………………. 81 
27. Peritoneal Macrophage MiRNA-21 Expression after Cecal Ligation and 
Puncture………………………………………………………………….. 90 
28. Peritoneal Exudate Cell counts after Cecal Ligation and Puncture… 91 
xii 
 
29. Peritoneal Macrophages after Cecal Ligation and Puncture……… 92 
30. Peritoneal TNF-α after Cecal Ligation and Puncture……………….. 93 
31. Peritoneal IL-6 after Cecal Ligation and Puncture…………….……. 94  





Peritonitis is regularly seen as part of clinical surgical practice. It can have 
multiple causes, resulting in bacterial infection within the peritoneal cavity of the 
abdomen. These include appendicitis, diverticulitis with perforation, and 
perforated bowel from a variety of other causes. Patients with peritonitis can 
have a variable disease course, from a mild, self-contained infection, through a 
whole body septic response potentially leading to multi-organ failure and 
potential fatality. It is a frequent cause for admission to the hospital and the 
surgical intensive care unit 1. Although improvements in critical care have led to 
more patients surviving, there has been little change in the treatment of 
peritonitis in the last 50 years 2. The mainstay remains 1) source control by 
removal, debridement, and/or drainage of infected and necrotic tissue; 2) 
antibiotics directed at Gram negative pathogens including anaerobes; and 3) 
supportive treatment of homeostatic functions in various organs such as the 
lungs, liver, kidneys, heart and gut.  
Mortality is directly associated with an exaggerated pro-inflammatory innate 
response with development of sepsis and organ failure 3. Several immune 
modulators have undergone clinical trials in recent years with the aim of 
manipulating the immune response to the benefit of the patient, but none have 
2 
 
successfully been able to change patient outcomes. The purpose of this work is 
to investigate specific mechanisms by which the response of peritoneal 
macrophages to endotoxin and bacterial infection are regulated and identify 





A. Clinical Importance of Peritonitis 
Peritonitis is inflammation of the lining of the peritoneal cavity that occurs in 
response to local irritation or infection. It can be categorized into primary, 
secondary and tertiary 4, 5. Primary or spontaneous bacterial peritonitis is 
relatively rare and occurs in ascites and liver failure. Secondary bacterial 
peritonitis is usually caused by a perforation, when enteric bacteria from the 
bowel are released into the peritoneal cavity and is our primary focus for these 
studies. Tertiary peritonitis is the persistence of bacteria despite adequate 
therapy, consisting of source control, drainage of any abscess and use of 
appropriate antibiotics 4, 6. Chemical peritonitis is less common, and occurs when 
blood, acid, bile, pancreatic juice, or other bodily fluids are released into the 
peritoneal cavity in the absence of infection.  This usually occurs in the setting of 
surgical complications and trauma 7. 
Secondary bacterial peritonitis is a common cause of surgical sepsis and has 
multiple etiologies, stemming from ischemia or perforation of the bowel that leads 
to enteric bacteria within the peritoneal cavity 2. The most common causes are 
inflammatory processes such as diverticulitis and appendicitis, but can also 
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include traumatic injuries and colon cancers eroding through the bowel wall. 
Peritonitis can be a spectrum of disorders, ranging from a contained local 
irritation, such as that associated with a benign appendicitis to pancreatic 
necrosis and intestinal ischemia that are often associated with substantial 
morbidity and mortality 5, 8. Several scoring systems such as the Mannheim 
Peritonitis Index and the Acute Physiology and Chronic Health Evaluation 
(APACHE) II score have evolved to try to predict those with a risk of increased 
morbidity and more complicated disease course 4, 9-13.  
The treatment of peritonitis has remained unchanged for the last 50 years; 
antibiotics directed at the offending gram negative aerobic and anaerobic 
bacteria and source control of the infection by open or laparoscopic resection, 
debridement, and drainage or percutaneous drainage. A recent Cochrane review 
concluded that no specific recommendations could be made about the first line 
antibiotics, as all included in the studies were equivalent, and included antibiotics 
active against gram negative aerobes and anaerobes 14. Despite treatment, 
peritonitis may progress to sepsis, a systemic inflammatory response to a source 
of infection, consisting of fever, tachycardia, tachypnea, and leukocytosis and 
multi-organ dysfunction. The Dutch registry for intensive care shows 
approximately 2.5% of all intensive care admissions are due to intra-abdominal 
infection combined with sepsis 15. 
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Despite clinically proven treatment and the ability to predict those with a higher 
risk of morbidity and mortality, it remains unknown why some patients are unable 
to contain and eliminate such an infection, resulting in a persistence of bacteria in 
the peritoneum. Some have theorized that this is because of a failure of the host 
immune response to clear the infection, and that augmentation or modulation of 
the immune response may serve to enhance the clearance of bacteria in these 
patients. Some patients go onto a persistent inflammatory state and develop 
organ failure, despite adequate source control, which is also a source of 
significant morbidity and mortality. Several immune-modulators have undergone 
clinical trials following success in a lab environment, however none have been 
successful in a clinical setting 16, 17.  
 
B. Immune Response Overview 
The immune response occurs in 3 phases: 1) The immediate innate (0-4 hours) 
response, which is recognition of the invading pathogen or tissue injury by 
preformed, non-specific and broadly specific effectors. 2) The early innate (4-96 
hours) which deals with the recognition of microbial-associated molecular 
patterns and in the inflammation, recruitment and activation of effector cells; and 
3) the adaptive (>96 hours) which consists of recognition by B and T cells and 
clonal expansion and differentiation into effector cells 18, 19. All these process act 
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synergistically to remove the infectious agent. This thesis will deal primarily with 
the early innate immune response in the first 96 hours of an infection. 
The innate immune system has evolved to be the first line of response to 
pathogens. It consists of the mechanical barriers to infection such as that seen in 
the skin epithelium and the mucosa of the bowel wall. The activation of 
complement and coagulation cascades impairs pathogen function, as well as 
activating the cellular component of the innate immune system 19. Pathogen 
associated molecular proteins (PAMPs) and damage associated molecular 
proteins (DAMPs) are released in response to pathogen invasion and are 
recognized by Pattern Recognition Receptors (PRRs) on the surface of immune 
cells 20. This combination of bacterial proteins and those released by damaged 
cells binds to PRR receptors such as Toll-like receptors (TLR), NOD-like 
receptors and Mannose-Binding Lectin that can be either cell associated in the 
membrane or cytosol or secreted to stimulate the immune system 19, 21. 
The major cells of the innate immune system are the macrophage and neutrophil 
both of which play an important role in the phagocytosis of bacteria, but the 
macrophage is the key orchestrator of the local reaction 19, 22.  Macrophages 
reside in the tissues and release mediators such as, cytokines and chemokines 
to induce inflammation as well as directly attacking microbes via release of free 
radicals, proteolytic enzymes and phagocytose invading pathogens 23, 24. This 
release stimulates the influx of neutrophils and subsequently monocytes and 
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macrophages from the peripheral circulation to assist in fighting the infection. The 
third main function of macrophages is antigen processing after phagocytosis and 
presentation to other immune cells which initiates the adaptive immune response 
with eventual specific antibody production 19. 
This pro-inflammatory response is followed by a regulated anti-inflammatory 
response which dampens down any excessive inflammation, to reduce the 
damage to surrounding normal tissue 19. Often there is a dysfunctional early 
innate immune response that does not respond appropriately to the infection, 
which can lead to an imbalance in the pro and anti- inflammatory responses, 
which is detrimental to the health of the organism 25.  
 
C. Macrophages 
Resident peritoneal cells include the mesothelial lining, mast cells and 
leucocytes. The human peritoneal resident leucocyte population comprises 45-
90% macrophages, 10-47% lymphocytes and the rest NK cells, dendritic cells 
and neutrophils 26. The mesothelial lining and macrophages are the main source 
of chemokines and cytokines that attract neutrophils and circulating monocytes to 
the peritoneum 18. Cytokines bind to cell surface receptors on target cells, 
inducing intracellular signaling cascades to induce, or inhibit cytokine-regulated 
genes in the nucleus, thus manipulating cell activity. IL-10 produced by 
macrophages inhibits neutrophil recruitment and chemokine generation, which in 
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turn inhibits pro-inflammatory cytokine release 27. Diffusion of inflammatory 
mediators TNF-α and IL-1β from the circulation plays an important role in the 
pulmonary activation of resident macrophages which results in the associated 
lung disease and neutrophil infiltration seen in animal models 28, 29. 
Toll-like Receptor signaling 
Host immune cells recognize foreign microbial pathogens by pattern recognition 
receptors located on their surface. The most studied of these are the toll-like 
receptors of which there are 12 in mice, and 10 in humans; most are located 
within the cell membrane, though TLR-3, -7, -8, -9, -11 and -13 are within the cell 
cytosol 19. TLR-4 is found on the cell membrane and responds to bacterial 
products such as lipopolysaccharide (LPS), derived from the outer membrane of 
gram-negative bacteria 30. Ligand binding to TLR-4 results in the activation of 
intracellular signaling and release of cytokines (Figure 1). In the unstimulated 
cell, the transcription factor, nuclear factor kappa B (NF-κB) is sequestered in the 
cytoplasm by inhibitory IκB proteins 31. When LPS binds to TLR-4, myeloid 
differentiation primary response gene 88 (MyD88) is activated to initiate intra- 
cellular signaling pathways. This leads to the phosphorylation of IκB by IκB 
kinases (IKKs), its subsequent degradation and allows the dissociation of NF-κB 
from the inhibitory complex and its nuclear translocation to stimulate gene 
expression 32. This stimulates the transcription of the pro-inflammatory cytokines 
notably Tumor Necrosis Factor-α (TNF-α) and Interleukin-6 (IL-6) 33, 34. TLR-4 
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Figure 1: Toll-like Receptor-4 signaling 
 
Overview of the Toll-Like Receptor 4 (TLR-4) signaling through MyD88 
dependent and independent pathways. Lipopolysaccharide (LPS),TRIF-related 
adapter molecule (TRAM), TIR-domain-containing adaptor-inducing interferon β 
(TRIF), Myeloid Differentiation Primary Response Gene 88 (MyD88), IL-1 
Receptor Associated Kinase (IRAK), TNF-Receptor Associated Factor 6 
(TRAF6), Mitogen Activated Protein Kinases pathway (MAPK), Extracellular 
Signal Related Kinase (ERK), c-Jun N-terminal Kinase (JNK), Inhibitory Kappa 
Kinase (IKK), Inhibitory Kappa Beta (Iκβ), Nuclear Factor Kappa Beta (NF-κB), 




also activates a MyD88-independent, TIR-domain-containing adaptor-inducing 
interferon β (TRIF) dependent pathway 32. MyD88-mediated signaling involves 
the activation of IL-1-Receptor associated kinases (IRAKs) 35. IRAKs activate 
TRAF6 (TNF-Receptor Associated Factor; central signaling protein of TLR-4 
pathway), which catalyses lysine 63 (K63) –linked ubiquitin chains. This TRAF6 
mediated ubiquitination is important in amplifying TLR-4 signaling by stimulating 
multiple downstream pathways, through IKK, NF-κB and the MAPKs, 
extracellular signal-related kinase (ERK), JNK and p38 to induce the genes 
coding for inflammatory cytokines 36, 37.  
 
D. MicroRNAs 
MicroRNAs (miRNAs) are short non-coding RNAs, 22-25 nucleotides long, which 
act to inhibit protein production 38. MiRNA are formed in the nucleus as pri-
miRNA, cleaved into the hairpin shaped pre-miRNA by Drosha and exported 
from the nucleus into the cytoplasm by Exportin-1 39. In the cytoplasm the miRNA 
are further cleaved by Dicer and incorporated into the RNA-induced silencing 
complex (RISC). The RISC then binds to the 3’ untranslated region (UTR) of 
messenger RNA (mRNA) to inhibit translation of proteins 40. If the sequences are 
100% complementary, then the mRNA is degraded, if the sequence is only 80% 
complementary, the mRNA remains intact, but unable to be translated into 
protein. MiRNA act as post-transcriptional modulators of protein translation 41. 
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There are >1000 miRNAs documented, each with hundreds of potential targets 
based on mRNA sequences, often experimentally unverified. There are multiple 
miRNAs known to target the TLR-4 signaling pathway 42.  
There has been a substantial increase in miRNA studies since the early 
discoveries made by Fire and Mellow 43. The essential role that miRNAs play in 
cell function and their possibilities as stable biomarkers mean that there is much 
still to learn about the influence of miRNAs. For example miRNA and 
transcription factors both regulate inflammation, and now there are examples of 
transcription factors regulating miRNA expression directly 40, 44.  As promoter 
regions of miRNAs are identified, a more focused understanding of their 
transcriptional regulation will emerge 45.  
 
MicroRNA-21 
MiRNA-21 has been the object of multiple studies due to its high abundance and 
significant role in cardiovascular injury, cancer progression and metastasis 46. 
The targets of miRNA-21 have roles in apoptosis, cell proliferation, cell migration, 
and invasion, and it has been shown to be up-regulated in multiple cancer types 
including but not limited to breast, lung, colorectal, hepatocellular, pancreatic and 
diffuse large B-cell lymphoma 46-49. MiRNA-21 has also been found in the plasma 
of patients with colorectal cancer 50.  MiRNA-21 is located on chromosome 17 in 
the 10th intron of the protein coding gene TMEM49 whose function is currently 
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unknown. It has its own promoter and expression is not affected by the TMEM49 
promoter 45.  Transcription is stimulated by NF-κB and knockdown of NF-κB by 
siRNA and inhibitors has shown to reduce expression of miRNA-21 in a nicotine-
induced cell proliferation model of gastric cancer 44, 51. LPS induces miRNA-21 
via TLR-4, MyD88 and NF B, which has a binding site in the miRNA-21 promoter 
region 52. The role of miRNA-21 in the immune system is still under active 
investigation, though it is believed to be involved in the transition between the pro 
and anti-inflammatory phases of the early innate immune response.  The miRNA-
21 targets that may contribute to this are Programmed cell death protein 4 
(PDCD4), Pelino 1 (Peli1), and Sprouty (SPRY) proteins 1, 2 and 4 53. 
 
Programmed Cell Death Protein 4 
PDCD4 has been validated as a target of miRNA-21 by independent groups 51, 54-
56. There is a single highly conserved miRNA-21 target site within the 3’UTR 
region, and it’s regulation by miRNA-21 has been reported in both human and 
murine cancer models 52.  Sheedy et al, show PDCD4 is a key step in the 
negative regulation of the inflammatory response to LPS 51. PDCD4-/- mice have 
been shown to have a lower mortality to LPS than PDCD4+/+ mice, associated 





There are 3 mammalian homologs of the Pelino (Peli) proteins 57 but only Peli1 
has so far been described as a likely target of miRNA-21 53. The Peli proteins, 
like TRAF6, function as E3 ubiquitin ligases and interact with the IRAKs, inducing 
ubiquitination of IRAK1, and thus have been linked to the regulation of TLR-4 
MyD88-dependent signaling 57, 58 as well as T cell activation 59, 60. Peli has also 
been demonstrated to be critical in TLR-3 activation of IKK and NF-κB, through 
interactions in the TRIF pathway 36. Peli interacts with TRIF-signaling adaptor 
kinase RIP1 and mediates RIP1 ubiquitination, a key step in the TRIF-dependent 
IKK-signaling pathway, and is critical in TRIF-dependent TLR signaling, though 
non-essential for MyD88-dependent TLRs 36. Peli1 has shown to be important in 
TLR-4-mediated gene induction, though only partially required for LPS stimulated 
activation of IKK and NF-κB (Figure 1). Peli1 is a proven target of miRNA-21 in 
liver regeneration, where Peli1 mRNA was inversely correlated with miRNA-21 
levels 61. Peli1 mRNA and protein expression is increased in macrophages that 
are stimulated by the TLR-4 ligand LPS, via a TRIF-dependent pathway, and 
independent of the MyD88-dependent pathway 62. The IKK-related kinases or 
IRAK1 activate Peli1 on macrophage stimulation through the TLR MyD88 






The Sprouty proteins were first described in 1998 as an inhibitor of fibroblast 
growth factor in Drosophilia 64. There are four 4 isoforms in mammals, and all are 
postulated targets of miRNA-21. Sprouty proteins inhibit signaling by receptor 
tyrosine kinases affecting the activation of MAPK. Srpy1, 2 & 4 block the 
activation of ERK (extracellular signal related kinase) in cells stimulated by 
growth factors, different points in the signaling cascade depending on the 
biological context 65-67. In mouse fibroblasts  SPRY1 and 2 inhibit ERK/MAPK 
signaling at the level of Ras activation, in human epithelial cells, SPRY2 acts on 
RAF1 as does mammalian SPRY4 68-70. All sprouty isoforms inhibit the ERK 
pathway by themselves, but heterodimers and homodimers have enhanced 
inhibition 71, 72.  In cardiac fibroblasts increased miRNA-21 is associated with 
decreased expression of SPRY1 and up-regulation of the ERK cascade 73.  
 
Signaling molecules NF-κB and ERK 
There are five members of the mammalian NF-κB family, RElA, RelB, c-Rel, p50 
and p52, which combine to form multiple dimeric complexes and activate target 
genes by binding to the enhancer element κB 74. As mentioned above, these 
proteins are sequestered in the cytoplasm by IκB proteins until the IκB proteins 
are phosphorylated and degraded by the proteasome allowing the NF-κB 
proteins to translocate to the nucleus to effect gene expression 75, 76. MiRNA-21 
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overexpression was associated with a ~40% decrease in NF-κB activity in HEK-
293 cells 61.  
ERK is one arm of the MAPK signaling pathway, triggered in response to TLR 
signaling 77, 78. The relationship between ERK activation and IL-10 production is 
not a simple one. Higher levels of ERK activation have been linked to higher IL-
10 production 79. 
 
Cytokines 
Tumor Necrosis Factor –α 
TNF–α is an important pro-inflammatory cytokine, the first one to be discovered 
as such with a plethora of effects when injected into animals including humans 
including fever, hypotension, metabolic acidosis and capillary leak 80-82. TNF-α 
plays a regulatory role in promoting local and systemic bacterial clearance 83. 
IL-6 
Interleukin-6 (IL-6) is released from macrophages in response to pathogens. It 
acts both locally to activate lymphocytes and increase antibody production, as 
well as systemically to induce fever, the production of acute phase proteins from 
the liver and neutrophil mobilization and migration to the focus of infection 19, 83. 
IL-6 correlates with mortality and IL-6 levels 6 hours from injury in a CLP model 
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predicts mortality 84 and has been shown to be the best biomarker of mortality in 
clinical sepsis 85. IL-6 is induced by NF B and augmented by PDCD4 51. 
IL-10  
Interleukin-10 (IL- 10), previously named cytokine synthesis inhibitory 
factor (CSIF), IL-10 suppresses both macrophage and dendritic cell function, 
including the ability to present antigens and the production of pro-inflammatory 
cytokines (IL-1β, TNF-α, and IL-12) 79. IL-10, as an important part of an anti-
inflammatory response, limits the immune and inflammatory responses to 
pathogens, which might otherwise result in collateral damage to the host 
organism 86, 87. IL-10 is constitutively transcribed in many cells, though post-
transcription regulations make the protein levels tightly regulated 88. Loh et al, 
show that PDCD4 inhibits translation by blocking the binding of translation 
initiation factor eIF4Gc to eIF4A in an inactive conformation 89. This is thought to 
be part of the mechanism by which IL-10 is suppressed by PDCD4, as PDCD4 
inhibits the cap-dependent translation of mRNAs with complex 5’ untranslated 
regions (UTRs), which include IL-10.  
 
E. Peritonitis Models  
The clinical infection of peritonitis that we see in our human surgical patients has 
been modeled using various several different methods. Each experimental model 
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has its value, depending on the hypothesis of the experiment. The use of animal 
models, which while not exactly the same physiologically as human, allows in 
vivo investigation into the mammalian physiology of normal or pathologic 
processes, and well as to investigate mechanisms of disease. These models 
may also serve to test the ability of an intervention to interrupt normal or 
pathologic processes and aid in the preclinical testing of potential therapeutic 
agents 16.  
The most common models of experimental peritonitis are cecal ligation and 
puncture (CLP) and endotoxin (LPS) 16. These are frequently performed in small 
animals due to cost considerations and the numbers required for 
experimentation. The defined characteristics of different strains and availability of 
genetic variants such as gene knockouts also make mice a useful model for 
peritonitis experiments.  
Lipopolysaccharide  
Lipopolysaccharide (LPS) or endotoxin is a common model of inflammation, 
especially in the mouse and has been a laboratory workhorse for decades. LPS 
is considered to be an important inducer of the septic response and 
intraperitoneal LPS is more likely to induce a hyperdynamic cardiovascular 
response than intravenous (IV)  administration and is thus a better model for the 
human condition 16. Induction of LPS peritonitis is simple, requiring only an intra-
peritoneal injection of the desired concentration of LPS in a standard carrier 
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volume, and can be performed readily with minimal practice. While this model 
gives a bolus of bacterial protein, and it has less clinical relevance because 
patients have a septic focus that slowly seeds bacteria into the body 90.  
Cecal Ligation and Puncture 
Cecal Ligation and puncture (CLP) is a well-established murine model of 
peritonitis that more closely models human peritonitis, as it combines the entry of 
enteric bacteria into the peritoneum, together with a foreign body reaction and an 
ischemic focus 16. A small incision is made in the abdomen, and the cecum 
externalized. The distal segment is ligated, ~1cm from the cecal pole and a 
puncture made in the ligated segment. The cecum in the mouse is a blind-ended 
tube, so no obstruction is caused by ligation of the bowel, when properly 
performed. The bowel is then returned to the abdomen and the peritoneum and 
skin closed in layers. The severity of the model can be varied with the length of 
bowel ligated and the size and number of punctures in the cecum 91. Cecal 
Ligation and puncture, in contrast to the LPS model, is a more time consuming 
cause of peritonitis, requiring superior surgical skills, and a more precise 
technique in order to consistently perform the same operation multiple times 
within the inherent variability in mouse anatomy. These animals develop an initial 
hyperdynamic cardiovascular response, similar to that seen in patients with 
increased cardiac output and decreased systemic vascular resistance 90. This 
develops into systemic bacteraemic infection and sepsis, which progressively 
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undergoes cardiovascular collapse due to septic shock and death days after the 
initial insult, similar to the condition seen in peritonitis patients who die from 
multiple organ failure days after the onset of infection. 
We propose to use both established models of peritonitis to examine the effect of 
miRNA-21 on both mechanistic and clinically relevant patterns of intra-abdominal 
infection. Existing data show that miRNA-21 acts on the TLR-4 pathway in 
response to LPS. If we are able to modify the balance of pro- and anti-
inflammatory immune response through manipulating the cytokines released in 
response to infectious stimuli, we may be able to affect survival and initiate the 




HYPOTHESIS, SPECIFIC AIMS AND EXPERIMENTAL PLAN 
 
 
A. Key Objective 
To investigate the role of miRNA-21 in the macrophage response to 
peritonitis, and identify whether the associated regulatory mechanisms 




We hypothesize that the outcome of peritonitis can be modulated by 
miRNA-21 through down regulation of NF-κB signaling that will affect 




C. Specific Aims 
1: To establish a time course of miRNA-21 expression in peritoneal 
macrophages following an infectious insult, either lipopolysaccharide or 
cecal Ligation and Puncture. 
2: To examine the mechanisms by which miRNA-21 regulates the 
inflammatory response.  
3: To investigate the effects of miRNA-21 on macrophage cytokine 
production 
4: To ascertain the effect of miRNA-21 knockout on survival in in vivo 
models of peritonitis - lipopolysaccharide or cecal ligation and puncture. 
 
D. Experimental Plan 
The overall goal of this project is to investigate the role of miRNA-21 in the 
macrophage response to peritonitis. We will establish the pattern of 
miRNA-21 expression and cytokine secretion from primary peritoneal 
macrophages. We will examine how modulation of miRNA-21 expression 
changes cytokine secretion. If we see a difference, we will investigate 
which targets of miRNA-21 that act on the TLR-4 signaling pathway are 
different between bone marrow derived macrophage cell lines from 
miRNA-21+/+ and miRNA-21-/- mice. Finally we will investigate the clinical 
potential for the use of miRNA-21 as a novel agent in peritonitis by 
comparing the survival of miRNA-21+/+ and miRNA-21-/- mice in LPS and 
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Approvals for the study protocols were obtained from the Robley Rex 
Veteran Affairs Medical Center and University of Louisville Institutional 
Animal Care and Use Committees (VA: che37, UofL: 11064). 
Wild-type Mice for Peritoneal Macrophage Experiments 
Male 6 week old C57BL/6 mice obtained from Jackson Laboratories (Bar 
Harbor, ME) were housed with food and water ad libitum according to 
IACUC guidelines.  
MiRNA-21 Knockout Mice and Wild Type Controls 
The gene targeting of miRNA-21 in mice was performed by inGenious 
Targeting Laboratory (iTL), Inc (Ronkonkoma, NY) as previously 
described 92. Briefly a targeting vector was constructed and transfected 
into hybrid embryonic stem cells by electroporation. Positive recombinant 
clones were identified by polymerase chain reaction (PCR). Targeted iTL 
BA1 hybrid embryonic stem cells were microinjected into C57BL/6 
blastocysts. Resulting chimeras were mated to wild-type C57BL/6 mice to 
generate F1 heterozygous offspring with germline transmission. Mice were 




Figure 2: Outline of Study 
 
 
The study begins with the peritoneal macrophage response, and then utilizes 
both miRNA-21+/+ and miRNA-21-/- bone marrow macrophage cell lines to 
delineate the impact of miRNA-21 on the cellular response to lipopolysaccharide. 
In vivo models of peritonitis are then used to assess the effect of miRNA-21 in a 
whole body situation.  
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Bone Marrow Macrophage Cell Lines 
Immortalized macrophage cell lines (BMM) were established by infecting 
the bone marrow of miRNA-21+/+ and miRNA-21-/- mice with the murine 
recombinant J2 retrovirus containing the v-myc and v-ref oncogenes as 
previously described 33, 93, 94. Cells were cultured in RPMI-1640 medium 
with 5% Fetal Bovine Serum, 1% L-glutamine, 1% HEPES and 0.1% 
gentamicin (all Sigma Aldrich) at 37°C in a humidified incubator with 5% 
CO2. 
 
ii. Harvest of Peritoneal Cells  
Naïve mice were anaesthetized with 2-3% isoflurane (Butler Schein, 
Dublin, OH) and the abdomen lavaged with 3mL of heparinized phosphate 
buffered saline (PBS) with no calcium or magnesium (Sigma Aldrich, St. 
Louis, MO). Lavage fluid was centrifuged to pellet peritoneal exudate cells 
(PECs) for macrophage isolation.  
 
iii. Macrophage Isolation 
Naive Mice – CD11b 
Magnetic bead isolation products were purchased from Miltenyi Biotec 
(San Diego, CA). PECs from each mouse were resuspended at 107 cells 
in 80μL autoMACSTM running buffer, and incubated at room temperature 
for 15min with CD11b beads. After washing, the cells were resuspended 
in 500μL Running Buffer and passed through MS columns in a 
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MiniMACSTM Separator magnet.  After isolation the columns were washed 
three times and eluted with 1mL running buffer and the isolated 
macrophages counted. This macrophage enriched population was 
manually quantified by hemocytometer with trypan blue exclusion method 
to determine total macrophage numbers and cell viability. 
 
CD11b beads were used to isolate the peritoneal macrophages from naive 
mice, as CD11b forms part of the C3 complement receptor with CD18. In 
mice it is strongly expressed on monocytes, macrophages and microglia. 
There are lower levels of expression on granulocytes including 
neutrophils, NK cells, CD5+ B cells and subsets of dendritic cells. F4/80 is 
present on all mouse macrophages; however there is not a F4/80 bead 
available. Preliminary experiments confirmed that >82% of CD11b+ cells 
isolated from the peritoneum of naïve wild type mice were F4/80+ (Figure 
3).  
 
After Cecal Ligation and Puncture – F4/80 
PECs were resuspended at 107 cells in 80μL PBS and incubated at 4°C 
for 25min with F4/80 R-Phycoerythrin (PE) antibodies (eBiosciences). 
After washing, the cells were resuspended in autoMACSTM running buffer 
and incubated with anti-PE beads (Militenyi Biotec) for a further 25 min at 
4°C. After a further wash, the cells were resuspended in 500μL running 
buffer and passed through MS columns (Militenyi Biotec) in a MiniMACSTM  
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Figure 3: CD11b isolation of Peritoneal Macrophages 
 
A) The cell population from the peritoneum of naïve wild type mice was gated the 
according to size (forward scatter – FSC) and granularity (side scatter – SSC). B) 
Cells were stained to ascertain distinct populations (CD3+ – T cells, CD19+ - B 
cells, CD 11b+ – myeloid cells, F4/80+ - macrophages). C) CD3-CD19- cells were 





Separator (Militenyi Biotec) magnet.  After isolation the columns were 
washed three times and eluted with 1mL running buffer and the 
macrophages counted. This macrophage enriched population was 
manually quantified by hemocytometer with trypan blue exclusion method 
to determine total macrophage numbers and cell viability. 
 
Following CLP there is an influx of neutrophils and circulating 
monocytes/macrophages into the peritoneum. These neutrophils are 
CD11b+; therefore to prevent a significant population of neutrophils within 
our macrophage samples, we performed the two-step isolation procedure. 
The purity of the isolated macrophages was >80% as determined by flow 
cytometry. 
 
iv. Lipopolysaccharide Stimulation 
For most experiments the macrophages were suspended at 0.5x106/mL in 
RPMI-1640 medium with 10% fetal bovine serum, 1% L-glutamine and 1% 
antibiotic/antimycotic all from Sigma Aldrich (St. Louis, MO) and plated in 
a 24 well plate at 0.5x106/1mL per well. Cells were rested overnight at 
37°C in a humidified incubator with 5% CO2 prior to stimulation. Samples 
were stimulated with lipopolysaccharide (LPS) 100ng/mL (E.Coli 011:B4; 
Sigma Aldrich). After stimulation cells were incubated for the indicated 
time periods. The culture media was removed and stored at -80°C for 
cytokine quantification. Macrophages were allocated to either RNA 
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isolation or lysed in 100μL of RIPA buffer (Sigma Aldrich) for protein 
quantification and western blot. 
 
The macrophages were rested overnight following isolation and prior to 
stimulation. We have previously observed activation of 
monocytes/macrophages by centrifugation, changing cytokine profile. In 
order to see the response to a single LPS challenge, and avoid any 
tolerance effects we allowed the cells to rest prior to LPS stimulation.  
 
v. RNA Isolation 
Total RNA was isolated from the macrophages using mirVana miRNA 
isolation kits (Ambion, Life technologies) following manufacturer’s 
protocol. RNA concentrations were determined and RNA purity was 
assessed using the NanoDrop 2000 (Thermo Scientific, Hudson, NH). All 
sample fulfilled the quality criteria (A260/280 ratio between 1.8 and 2.1). 
 
vi. MiRNA and MessengerRNA Expression 
MiRNA-21 expression was measured using Taqman® single miRNA 
assays and Taqman MiRNA Reverse Transcription Kit for miRNA (Applied 
Biosystems®, Life Technologies). U6 was used as a house keeping gene 
miRNA for normalization.  
For mRNA expression RNA was transcribed into complementary DNA 
(cDNA) using High Capacity cDNA Reverse Transcription Kit for mRNA 
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(Applied Biosystems®). Taqman single gene assays for PDCD4, Peli1, 
SPRY1, SPRY2, and SPRY4. 18s was used as an internal control. 
The StepOne Plus (Applied Biosystems®) was used to run the real time 
Polymerase Chain Reaction (PCR) using Fast Advanced Master Mix and 
the fast protocol (all products Life Technologies). StepOne Plus software 
v2.1 (Applied Biosystems®) generated Cycle Threshold (CT) values which 
were used to calculate fold changes using the ΔΔCT-method 95. 
 
vii. Cytokine Assays 
TNF-α, IL-6 and IL-10 levels were measured in lavage media and culture 
media supernatants using enzyme-linked immunosorbent assays 
(ELISAs).  Murine Ready-Set-Go kits were purchased for all ELISAs from 
e-Biosciences (San Diego, CA, USA) and then performed in 96-well plates 
according to the manufacturer’s instructions. All samples were analyzed in 
duplicate. Where necessary, samples were diluted in assay diluent to 
achieve cytokine concentrations within the range of the standard curve.   
 
viii. Protein isolation  
Protease and phosphatase inhibitors (Thermo Scientific) were added to 
proteins in RIPA buffer and sonicated using a Sonifier 250 (Branson 
Ultrasonics Danbury, CT). Protein quantification was determined by BCA 
Assay (Thermo Scientific, Rockford, IL) against a standard curve on 
Dynatech MR4000 using BioLinx 2.0 software.  
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ix. Western Blot  
All products for Western Blots were purchased from Life Technologies 
(Carlsbad, CA) unless otherwise specified and run according to 
manufacturer’s protocols. 40μg of protein per sample was loaded into 
wells of a Bolt 4-12% Bis-Tris Plus mini gel with 4x BoltTM LDS Sample 
Buffer with 1:100 2-mercaptoethanol, and run in Bolt MES SDS Running 
Buffer in a Bolt Mini Gel Tank on a Bio-Rad Power Pac 1000 (Hercules, 
CA) at 165mV for 35-60 min with SeeBlue® Plus2 Prestained Standard. 
Proteins were transferred onto Nitrocellulose membrane using iBlot® Gel 
Transfer stacks and an iBlotTM transfer device.   
Non-specific binding was blocked with 7% non-fat milk in TBS-T (9.68g 
Tris base, 32g sodium chloride in 100mL ddH2O (pH adjusted to 7.6 with 
concentrated hydrochloric acid), with 100μL Tween 20) for 1 hour at room 
temperature. The membranes were incubated with rabbit anti-mouse 
primary antibody overnight at 4°C. 
All antibodies were purchased from Cell Signaling (Danvers, MA) unless 
otherwise specified. All antibodies were suspended in 5% milk non-fat milk 
made with TBS-T for 1-2 hours at room temperature or overnight at 4°C. 
Antibody concentrations were as follows: Peli1 1:250 (Thermo Scientific), 
PDCD4 1:500, SPRY1 1:200 (Santa Cruz Biotechnology, Inc, Dallas, TX), 
SPRY2 1:1000, and SPRY4 1:500 (Thermo Scientific).   
Following incubation with each antibody, membranes were washed three 
times with TBS-T for 10 minutes. Subsequently the membranes were 
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incubated with rabbit anti-mouse primary antibody for housekeeping 
protein β-actin (1:10,000) or glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH 1:10,000) and then with goat anti-rabbit secondary antibody 
(1:5,000). 
Pierce ECL Western Blotting Substrate (Thermo Scientific) was applied to 
the membrane as per the manufacturer’s instructions. CL-XPosureTM Film 
(Thermo Scientific) was used to expose the membrane for 15min. The 
resultant image was developed, fixed, scanned and quantified using 
ImageJ (National Institutes of Health, Bethesda, MD). 
 
x. MiRNA Transfection 
To elucidate the anti-inflammatory effect of miRNA-21 on the macrophage 
expression of cytokines, we transfected primary peritoneal macrophages 
with mimics and antagomirs. MiRNA mimics are double-stranded RNAs 
that are processed by Dicer and are incorporated into the RISC, acting in 
the same way as endogenous miRNAs. The miRNA inhibitors in contrast 
are single-stranded anti-sense RNAs that bind to the target miRNA which 
leads to its degradation. The negative control has a hairpin structure like 
the endogenous pre-miRNA, and is also processed by Dicer, but the 
sequence is not complementary to any known gene, and therefore has no 
active function with the cell. 
For this experiment, the primary peritoneal macrophages from naïve wild 
type C57BL/6 mice were suspended at 0.42x106 in RPMI-1640 medium 
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with 10% fetal bovine serum, 1% L-glutamine and 1% 
antibiotic/antimycotic. Cells were immediately transfected. MirVana® 
mimic, inhibitor and negative control to mmu-miR-21-5p (Life technologies, 
Carlsbad, CA) were assembled with N-TER peptides (Sigma Aldrich) as 
per manufacturer’s protocol.  
0.25 x106 macrophages were incubated in a concentration of 120nM of 
mimic, antagomir, or negative control for 24 hours in at 37°C with 5% CO2 
in cell suspension. After 24 hours, the samples were diluted with a further 
600μL of media and stimulated with LPS 100ng/mL. Six or 24 hours after 
LPS stimulation, the culture media was collected for cytokine 
measurement and the macrophages processed for RNA isolation and 
subsequent analysis of miRNA expression. An N of 1 was used for 
macrophages from a single mouse used for mimic, antagomir, and 
negative control.  
 
xi. Phosflow Pathway Analysis 
Immortalized macrophages from miRNA-21+/+ and miRNA-21-/- mice were 
resuspended at 0.5x106/mL RPMI-1640 medium with 10% fetal bovine 
serum, 0.5% L-glutamine and 0.5% antibiotic/antimycotic. Cells in 
suspension were rested overnight at 37°C in a humidified incubator with 
5% CO2 prior to stimulation. After stimulation with LPS (100ng/mL), cells 
were incubated for the indicated time periods. For baseline pathway 
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activation determination, similarly cultured unstimulated miRNA-21+/+ and 
miRNA-21-/- macrophages were used.   
Following the indicated time, the cells were fixed immediately with 
formaldehyde (3.2% pre-warmed), to maintain the phosphorylation status 
of the pathways. After washing, cells were permeablized with chilled 100% 
methanol. Cell samples were split for analysis of NF-κB or ERK activation. 
Intracellular staining occurred in the dark for 1 hour with phospho-NF-κB 
p65 or phospho-ERK AlexaFluor® 488 antibodies (Cell signal, Danvers, 
MA). After staining, cells were washed and resuspended in 300μL FBS-
stain buffer (2% FBS in PBS, both Sigma Aldrich). 
A FACS Calibur (BD Bioscience, San Jose, CA) was used to acquire the 
samples. We counted 10,000 events for each sample. CellQuest Pro (BD 
Bioscience) was used for analysis. 
 
xii. Peritonitis Models 
Lipopolysaccharide Peritonitis 
Male C57BL/6 miRNA-21+/+ and miRNA-21-/- mice aged 12-18 weeks were 
weighed, single housed and fasted for 3 hours prior to intra-peritoneal 
injection of 25mg/kg of E. coli LPS (E.Coli 055:B5; Sigma Aldrich). Surface 
temperature, daily weight and survival were recorded for up to 5 days. 
Mice were given food and water ad libitum. Preliminary experiments found 
the optimal dose for a 50% survival in the wild type mice was 25mg/kg 
with 3 hours of fasting prior to induction of peritonitis (Figure 4). 
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Figure 4: Lipopolysaccharide Peritonitis Survival Curves 
 
Multiple survival experiments were performed in wild type mice to find the optimal 
dose for a survival of 40-60%. 25mg/kg with 3 hour fast was selected for final 










Cecal Ligation and Puncture Peritonitis 
Male C57BL/6 miRNA-21+/+ and miRNA-21-/- mice aged 12-18 weeks were 
weighed prior to undergoing cecal ligation and puncture.  Briefly, under 
isoflurane anesthesia, the abdomen was incised and, the cecum 
exteriorized and ligated 1cm from the tip. A through and through puncture 
was made with a 20G needle, and the cecum returned to the abdomen. 
The peritoneal layer was closed with 3-0 Ticron and 50μL of 2% lignocaine 
applied to the suture line. Skin was closed with 3-0 silk. Post-operatively 
mice were given 600μL subcutaneous 0.9% saline and single housed.  
Surface temperature, daily weight and survival were recorded for up to 5 
days. Mice were given food and water ad libitum. 
 
xiii. Statistical Analysis 
Data are shown as the mean ± standard error. Sigma Plot 13.0 (Systat 
Software Inc, San Jose, CA) was used to perform Student’s t-test, ANOVA 
and Linear Regression to determine statistical significance. A p value of 





MIRNA-21 EXPRESSION IN PERITONEAL MACROPHAGES 
Introduction 
Recent studies have shown a role for miRNA-21 in the regulation of the TLR-4 
pattern recognition receptor, which is present on macrophages amongst other 
cells 42, 51. TLR-4 activation leads to the initiation of the innate immune response 
and release of pro- and anti-inflammatory cytokines. The expression of miRNA-
21 has been shown to increase in RAW264.7 cells following LPS stimulation 51. 
The pattern of expression in primary peritoneal macrophages has yet to be 
ascertained. We propose that miRNA-21 expression in primary peritoneal 




MiRNA-21 expression increased in a linear fashion following LPS stimulation of 
primary peritoneal macrophages to maximum fold change of 12 in the 
observation period (R2=0.82, Figure 5). 
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A) Peritoneal macrophage miRNA-21 expression after lipopolysaccharide (LPS) 
stimulation. N=8. B) Linear Regression R2 = 0.82, P = <0.001. Data are shown 




Secreted Cytokine Profile  
The pro-inflammatory cytokines TNF-α and IL-6, were increased from 15min after 
LPS stimulation (Figure 6). The levels of TNF-α peaked at 6 hours, were 
somewhat decreased at 24 hours, but after that remained elevated. IL-6 peaked 
at 12 hours and then plateaued. The anti-inflammatory cytokine IL-10 was also 
increased from 15min after LPS stimulation, rising to a peak at 12 hours, and 
then decreasing to 60% of maximum at the end of the observed period (Figure 
7).  
MiRNA-21 target mRNAs 
The mRNA levels of the miRNA-21 target PDCD4 decreased sharply for the first 
3 hours following LPS stimulation (Figure 8). This was followed by an increase 
until 36 hours, and a subsequent decline, but always remained below baseline 
levels. 
Peli1 mRNA levels increased following LPS stimulation to a peak at 3 hours 
(Figure 9). Levels returned to baseline at 24 hours and remained there for the 
remainder of the observation period. 
SPRY1 and 4 followed a pattern similar to Peli1, with an initial peak at 1 hour, 
then returning to baseline around 24 and 6 hours respectively (Figure 10). 
SPRY1 remained at baseline, while SPRY4 became down-regulated from 24 
hours. SPRY2 has an initial increase and return to baseline within the first 3 
hours, followed by a slower, greater increase in mRNA levels over 36 – 96 hours 
which then declined.  
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Figure 6: Peritoneal Macrophage Pro-inflammatory cytokines after 
Lipopolysaccharide 
 
TNF-α and IL-6 concentrations from media of peritoneal macrophages after 
lipopolysaccharide (LPS) stimulation. A) TNF-α and B) IL-6. N=8. Data are 




Figure 7: Peritoneal Macrophage Anti-inflammatory cytokine after 
Lipopolysaccharide 
 
IL-10 concentrations from media of peritoneal macrophages after 
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Figure 8: Peritoneal Macrophage PDCD4 mRNA expression after 
Lipopolysaccharide 
 
Peritoneal macrophage PDCD4 mRNA fold change after lipopolysaccharide 





Figure 9: Peritoneal Macrophage Peli1 mRNA expression after 
Lipopolysaccharide 
 
Peritoneal macrophage Peli1 mRNA fold change after lipopolysaccharide (LPS) 





Figure 10: Peritoneal Macrophage SPRY mRNA expression after 
Lipopolysaccharide  
 
Peritoneal macrophage mRNA fold change after lipopolysaccharide (LPS) 






We found that there is a linear increase in the expression of miRNA-21 following 
LPS stimulation in primary peritoneal macrophages. This observation is 
consistent with previous data in a RAW264.7 mouse macrophage immortalized 
cell line 51.  
The observed rise in TNF-α, IL-6 and IL-10 following stimulation of our 
macrophages-enriched population occurs, concurrently. More recent perceptions 
of the interactions between pro- and anti-inflammatory responses to LPS 
stimulation have noted that these responses occur simultaneously,  though the 
downstream effects maybe more delayed in the classical anti-inflammatory 
response 25. The initial decrease in the mRNA levels of PDCD4 and the steep 
increase seen in Peli1, SPRY1 and 4 are due to the initial stimulation with LPS. 
MiRNA-21 is induced steadily over time, and needs to be incorporated into the 
RISC before these miRNAs can act to reduce mRNA levels or affect protein 
translation. A delay in miRNA action is therefore expected. Together these data 
do not give an obvious picture of miRNA-21 effects on target mRNA and 
subsequent cytokine production. Confirmation of the regulatory effects of miRNA-
21 on TLR-4 signaling, requires modulation of miRNA-21 expression. The 
macrophages were rested overnight following isolation and resuspension at the 
required concentration. We have seen previously that centrifugation is able to 
activate macrophages, changing cytokine profiles, therefore in order to see the 
response to a single LPS challenge, and avoid any tolerance effects, we allowed 
the cells to return to a ‘normal’ state prior to LPS stimulation. 
45 
 
Our observation period ended at 120 hours, as attempts at longer periods of 
observation resulted in unviable primary peritoneal cells. The miRNA-21 
expression was still increasing at that time point, and it would be advantageous 
to understand for how long the miRNA-21 levels increase following LPS 





MIRNA-21 HAS ANTI-INFLAMMATORY EFFECTS IN PERITONEAL 
MACROPHAGES 
Introduction 
We have seen that miRNA-21 expression is increased in peritoneal 
macrophages after LPS stimulation in vitro. The purpose of the next series of 
experiments was to confirm the proposed anti-inflammatory role of miRNA-21 on 
the production of TNF-α and IL-10. Based on our search of available literature, 
we propose that miRNA-21 decreases TNF-α and increases IL-10 production by 
a dual mechanism. Two proven targets of miRNA-21, PDCD4 and Peli1 are 
positive regulators of the TLR -4 signaling pathway 36, 51, 61. Inhibition of PDCD4 
and Peli1 by miRNA-21 decreases the signaling of the TLR-4 pathway and 
results in a decreased expression of TNF-α and its translation into protein, which 
is then secreted. In contrast, the SPRY proteins are negative regulators of the 
TLR-4 signaling pathway.  Inhibition of SPRY expression leads to an increase in 
ERK activation which leads to an increase in IL-10 expression and production. 
Successful modulation of TNF-α and IL-10 secretion by manipulation of miRNA-
21 expression may have potential therapeutic applications. For this purpose we 
modulated the expression of miRNA-21 in primary peritoneal macrophages with 





Over-expression and Suppression of miRNA-21 
Transfection of both mimics and antagomirs into primary peritoneal macrophages 
was successful (Figure 11). The mimics achieved on average 1000- and 56-fold 
increase in miRNA-21 levels at 6 and 24 hours respectively (P<0.001 and 0.029). 
The antagomirs suppressed miRNA by 8-fold at 6 hours (p<0.001) after LPS and 
37-fold after 24 hours though this was not statistically significant. Mimic and 
antagomir miRNA-21 levels were compared to the negative control at that time 
point.  
Effect of miRNA-21on TNF-α at 6 and 24 hours 
Manipulation of miRNA-21 expression led to changes in TNF-α concentration at 
both 6 and 24 hours after LPS stimulation (Figure 12). Over-expression of 
miRNA-21 resulted in a significant decrease in TNF-α at 6 hours (p=0.037) but 
not 24 hours. Suppression of miRNA-21 significantly increased the TNF-α 
produced at both 6 hours (p=0.037) and 24 hours (p=0.012).  
Effect of miRNA-21on IL-10 at 6 and 24 hours 
Modulation of miRNA-21 levels did not affect the levels of IL-10 at either time 
point after LPS stimulation (Figure 13). At 24 hours there was a trend towards 
increased IL-10 in the mimic-transfected macrophages; however the effects were 
not consistent between mice. 
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Figure 11: MiRNA-21 Expression after Transfection 
 
Transfection with MiRNA-21 Mimic led to significant over expression of miRNA-
21 at both 6 and 24 hours after lipopolysaccharide (LPS) stimulation. The use of 
antagomirs led suppressed miRNA-21 expression at both points, though only 








Figure 12: Effect of MiRNA-21 on TNF-α  
 
Modulation of miRNA-21 expression showed the expected results. Suppression 
of miRNA-21 significantly increased TNF-α. Over expression significantly 
reduced TNF-α at 6 hours after lipopolysaccharide (LPS) stimulation but not after 







Figure 13: Effect of MiRNA-21 on IL-10  
 
Modulation of miRNA-21 expression was not successful in modulating IL-10 
secretion in primary peritoneal macrophages at either time point after 




























MiRNA-21 has anti-inflammatory effects on the primary peritoneal macrophage 
response to LPS. MiRNA-21 decreases the activation of the TLR-4 pathway by 
inhibiting PDCD4 and Peli1. These in turn decrease the activation of NF-κB and 
the transcription of TNF-α, its translation into protein and subsequent release 
from the macrophage in response to LPS. We proposed that miRNA-21 acts to 
ameliorate the pro-inflammatory response by reducing levels of pro-inflammatory 
cytokines such as TNF-α, though regulation of the TLR-4 MyD88 signaling 
cascade, likely through the actions of proved targets PDCD4 and Pelino1. 
MiRNA-21 also targets the Sprouty proteins which inhibit signaling in the ERK 
arm of the MAPK signaling cascade, suggesting an increase in miRNA-21 levels 
would also increase IL-10 production. 
We have seen in previous experiments that miRNA-21 is induced in primary 
peritoneal macrophages by stimulation with LPS (Figure 5) 51. At 6 hours we 
have a 1000 fold increase in miRNA-21 and only a 64 fold increase at 24 hours. 
This is due to the normalization of miRNA-21 in the transfection samples. 
MiRNA-21 levels in the negative control are physiologically lower at 6 hours 
compared to those seen at 24 hours, and therefore provide a lower baseline for 
comparison. Modulation of miRNA-21 expression is sufficient to significantly 
change TNF-α expression in all cases except in the mimic-transfected cells at 24 
hours. This may be due to competing endogenous RNAs (ceRNAs). Recent 
literature has suggested a new component to miRNA regulation, the miRNA 
sponge or ceRNAs 96-99. These miRNA sponges contain multiple binding sites for 
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the miRNA of interest, and can act as effectively as artificial antisense 
oligonucleotides 100. Therefore the artificial up-regulation of miRNA-21 in 
peritoneal macrophages by mimics could be counteracted by a known or 
unknown mRNA target acting as a ceRNA. Each miRNA has hundreds of 
potential targets based on gene sequencing, with only a few experimentally 
verified. A miRNA sponge for miRNA-21 has not yet been identified, however 
PTEN, a target of miRNA-21 in tumor cells has been implicated in other networks 
101. 
In these experiments, miRNA-21 expression in peritoneal macrophages peaks at 
a 10 fold up-regulation at 120 hours after LPS stimulation. Contrastingly, we see 
a thousand fold up-regulation in the mimic-transfected macrophages, but this is 
still insufficient to elicit a significant change in the IL-10 production. There is no 
difference in IL-10 concentrations at either time point, though there is a trend 
towards higher levels in the mimic-transfected macrophages at 24 hours. We 
proposed that the effects of miRNA-21 on IL-10 production are regulated through 
the ERK signaling cascade.  MiRNA-21 inhibits the Sprouty proteins, which in 
turn inhibit the ERK cascade. There are 4 Sprouty isoforms, all of which are 
theoretical targets of miRNA-21. Higher levels of miRNA-21 may be required to 
sufficiently inhibit the protein levels, in order to see a change in IL-10 production, 
even at 24 hours. We have shown that successful transfection of peritoneal 
macrophages results in changes in TNF-α concentrations, which are directly 




MIRNA-21 HAS ANTI-INFLAMMATORY EFFECTS IN BONE MARROW 
MACROPHAGES 
Introduction 
In previous experiments we have seen that successful inhibition of miRNA-21 
with antagomir-transfected primary peritoneal macrophages resulted in lower 
levels of TNF-α production. The purpose of the next experiment was to confirm 
these results in a macrophage cell line utilizing miRNA-21+/+ and miRNA-21-/- 
bone marrow derived macrophage cell lines. Inhibition of endogenous miRNAs 
with transfection is often incomplete, as transfection efficiency can vary from cell 
to cell within a treated sample. However, the use of an immortalized cell line from 
transgenic mice will likely yield novel data as to the importance of the gene in 
regulation of the TLR-4 signaling pathway.  
We propose that using the miRNA-21-/- bone marrow derived macrophage cell 
line will add important additional data regarding miRNA-21 regulation of the 




Effect of miRNA-21 knockdown on TNF-α  
MiRNA-21 knockdown was confirmed by PCR. Knockdown of miRNA-21 
expression led to changes in TNF-α concentration from 6 hours after LPS 
stimulation (Figure 14). TNF-α concentration was significantly higher at 6 and 24 
hours (p<0.05), and trending towards significance at 48 hours (p=0.059) in the 
miRNA-21-/- macrophages.  
Effect of miRNA-21 knockdown on IL-6  
IL-6 concentration also changed after LPS stimulation in miRNA-21-/- 
macrophages (Figure 15). IL-6 was significantly higher at 24 and 48 hours 
(p<0.05) in the miRNA-21-/- macrophages.  
Effect of miRNA-21 knockdown on IL-10  
Knockdown of miRNA-21 expression led to changes in IL-10 concentration at 
early time points after LPS stimulation (Figure 16).  The concentration of IL-10 in 
the cell culture media was significantly lower from 1 hour after LPS in the miRNA-
21-/- macrophages and did not reach miRNA-21+/+ levels until 24 hours (p<0.05).  
Effect of miRNA-21 on target proteins 
PDCD4 protein abundance was similar in both miRNA-21+/+ and miRNA-21-/- 
macrophages both at baseline before LPS stimulation and 24 hours afterwards 
(Figure 17). No difference was detected in Peli1 protein abundance at 24 hours 
after LPS stimulation (Figure 18). SPRY 1 and 2 protein levels were not different  
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Figure 14: TNF-α in Bone Marrow derived Macrophages 
 
Knockdown of miRNA-21 led to significant increase in TNF-α levels following 
lipopolysaccharide (LPS) stimulation. N=8. Data are shown Mean ± SEM. 






Figure 15: IL-6 in Bone Marrow derived Macrophages 
 
Knockdown of miRNA-21 led to significant increase in IL-6 levels following 
lipopolysaccharide (LPS) stimulation. N=8. Data are shown Mean ± SEM. 
*indicates p < 0.05. 
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Figure 16: IL-10 in Bone Marrow derived Macrophages 
 
Knockdown of miRNA-21 led to significant decrease in IL-10 levels at early time 
points following lipopolysaccharide (LPS) stimulation. N=8. Data are shown Mean 
± SEM. *indicates p < 0.05 
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Figure 17: PDCD4 in Bone Marrow derived Macrophages 
 
Knockdown of miRNA-21 did not lead to a significant change in PDCD4 protein 
at A) Baseline or B) 24 hours following lipopolysaccharide (LPS) stimulation. N=3 




Figure 18: Peli1 in Bone Marrow derived Macrophages 
 
Knockdown of miRNA-21 did not lead to a significant change in Peli1 protein at 
24 hours following lipopolysaccharide (LPS) stimulation. N=4. Data are shown 




























between miRNA-21+/+ and miRNA-21-/- macrophages 24 hours after LPS 
stimulation (Figure 19). SPRY 4 protein was not detectable in either cell line after 
24 hours with LPS.  
 
Discussion 
Knockdown of miRNA-21 in the bone marrow derived macrophage cell line 
confirmed the anti-inflammatory effects of miRNA-21 seen on TNF-α 
concentrations in the antagomir-transfected primary peritoneal macrophages. 
Concentrations of another pro-inflammatory cytokine IL-6, were also significantly 
higher after LPS stimulation in miRNA-21-/- compared to miRNA-21+/+ 
macrophages, though at later time points. From our data in primary peritoneal 
cells, we observed that Peli1 mRNA expression is induced by LPS stimulation, at 
a faster rate than miRNA-21. The time taken for miRNA-21 to be transcribed, 
processed, incorporated into the RISC and to act on Peli1 mRNA may be the 
delay observed between LPS stimulation and the change in TNF-α production 
seen between miRNA-21+/+ and miRNA-21-/- macrophages.  
In the transfected primary peritoneal macrophages we were surprised not to see 
any changes in IL-10 concentration with either the mimics or antagomirs. The 
miRNA-21-/- macrophages had significantly lower levels of IL-10 at early time 
points after LPS stimulation. MiRNAs act by inhibiting protein translation; 
therefore if a miRNA is constitutively turned off, as in knockout cells, we propose 
that there will be higher baseline levels of that protein expressed within the cell.  
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Figure 19: SPRY 1 and 2 in Bone Marrow derived Macrophages 
` 
Knockdown of miRNA-21 did not lead to a detectable change in A) SPRY 1 or B) 
SPRY 2 levels at 24 hours following lipopolysaccharide (LPS) stimulation. N=4 






Sprouty proteins inhibit the ERK signaling cascade, which in turn leads to a 
reduced IL-10 expression; this correlates with the lower levels of IL-10 seen in 
the miRNA-21-/- macrophages, where we would expect to see higher levels of 
Sprouty.  
The observed changes in cytokine production between miRNA-21+/+ and miRNA-
21-/- cells leads to an expectation that we will detect associated differences in the 
miRNA-21 target proteins, with higher levels present in the miRNA-21-/- cell lines. 
There was a trend towards higher levels of PDCD4 at baseline (no LPS) in the 
miRNA-21-/- cell line (Figure 17A). However, at 24 hours no difference was 
detectable. 
PDCD4 protein has been shown to be reduced following LPS stimulation at 24 
hours in RAW264.7 cells, mouse bone marrow derived macrophages  and 
human peripheral blood monocytes, with the same dose as used in these 
experiments 51. Knockdown of PDCD4 protein levels was shown with pro-miRNA-
21 in RAW264.7 cells with and without LPS stimulation. This is contrary to what 
we saw in our results. This may be due to differences in cell culture 
concentrations, as we increased our cell concentration in order to increase the 
protein yield for western blot samples. The difference in protein levels may be 
more subtle than we are able to detect. 
We did not discern any significant difference between the levels of Peli1, SPRY 
1, 2 or 4 at 24 hours after LPS stimulation. Peli1-/- mice have been used to 
ascertain the impact of Peli1 on LPS signaling through TLR-4, however the link 
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between miRNA-21 and Peli1 has only been studied in liver regeneration, and 
there was no causal time delay between miRNA-21 up-regulation and the 
changes in Peli1 mRNA 36, 61. There are no data with which to compare our Peli1 
protein findings in macrophages after LPS.  
SPRY proteins have not previously been directly linked to TLR-4 signaling, 
though they have been shown to inhibit p38 in the MAPK pathway of interferon 
receptor signaling in mouse embryonic fibroblasts 102. The experimental 
verification of SPRY proteins as targets of miRNA-21 have occurred in other non-
macrophage cell types 73, 92. SPRY proteins are induced by ERK activation 66. 
The similarities between the abundance in both miRNA-21+/+ and miRNA-21-/- 
macrophage cell lines may be because the SPRY proteins do not have an 
important role to play in TLR-4 signaling. Further experiments using either 
silencing RNA (siRNA) or SPRY protein knockouts will add data to inform 
whether SPRY proteins modulate TLR-4 signaling. 
We have corroborated our previous data that miRNA-21 changes the 
macrophage cytokine profile in response to LPS stimulation. We believe that he 
likely candidate as the most important miRNA-21 target protein in regulating 




MIRNA-21 AFFECTS NF-ΚB AND ERK SIGNALING IN BONE MARROW 
MACROPHAGES 
Introduction 
Intracellular signaling pathways allow cells to respond to external stimuli. Pattern 
recognition receptors on both the cell surface and within the cell identify 
pathogen associated molecular proteins to activate an appropriate immune 
response. Two important pathways in macrophages are the NF-κB and MAPK 
pathways. Activation of these pathways results in the release of cytokines to 
orchestrate the immune response to the invading pathogen. Cytokines act both 
locally and systemically. Pro-inflammatory cytokine release leads to the local 
recruitment of immune cells from the vasculature, and also the development of 
the systemic acute phase response and fever. These effects combine to enhance 
host defense against such pathogens and directly combat the infection. 
Manipulation of these pathways therefore has the potential to affect the way 
macrophages respond to pathogens. MiRNA-21 has been shown to inhibit the 
production of PDCD4 and Peli1 proteins which both affect the TLR-4 signaling 
cascade 51, 61. Knockout of Peli1 affects NF-κB activation following LPS 
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stimulation 36. The ERK arm of the MAPK pathway in macrophages has been 
previously linked to IL-10 production 88. SPRY proteins have been shown to 
inhibit the ERK signaling pathway 66, 69, 103. SPRY proteins are targets of miRNA-
21 73, 92. 
We propose that knockout of miRNA-21 will lead to increased NF-κB activation 
which would explain the higher levels of TNF-α seen after LPS stimulation in 
these cells. We also hypothesize that decreased ERK activation in the miRNA-




Activation of the NF-κB pathway 
There was a maximal increase in the levels of NF-κB 10 minutes after LPS 
stimulation (Figure 20).  This elevation continued throughout the observed 2 hour 
period. There was no difference in activation between miRNA-21+/+ and miRNA-
21-/- bone marrow derived macrophages.  Where comparing relative activation, 
the cells were more similar. 
Activation of the ERK pathway 
The pattern of ERK phosphorylation after LPS stimulation is unclear (Figure 21). 
The relative activation shows a higher peak in the miRNA-21+/+macrophages 
than miRNA-21-/- cells. 
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Activation of NF-κB p65 subunit was not different between miRNA-21+/+ and 
miRNA-21-/- bone marrow derived macrophage cell lines after lipopolysaccharide 
(LPS) stimulation. A) Mean channel fluorescence B) Relative Activation. N=4. 
Data are shown Mean ± SEM.  
67 
 




Activation of ERK was not significantly different between miRNA-21+/+ and 
miRNA-21-/- bone marrow derived macrophage cell lines after lipopolysaccharide 
(LPS) stimulation. A) Mean channel fluorescence B) Relative Activation. N=4. 




Changes in TNF-α production have been shown to be associated with NF-κB 
activation 77, 78. However, we were unable to show an association in this 
experiment between the production of miRNA-21 and the activation of NF-κB 
despite changes in TNF-α between the cell lines (Figure 14). We did show the 
speed at which NF-κB is activated following LPS stimulation, and that it continues 
for at least 2 hours (Figure 20). There are 5 subunits of NF-κB, and we only 
studied activation of p65, it may be that another subunit is important for miRNA-
21 related effects, as the NF-κB p50 subunit is the key regulator in LPS-tolerant 
transition to a M2 polarized phenotype in macrophages 104.  
The pattern of ERK activation seen in our bone marrow macrophage cell lines is 
unclear. The relative activation shows a higher peak in the miRNA-21+/+ 
macrophages which has been noted to correlate with higher IL-10 levels 79, 88. 
The absence of a difference seen between these cell lines maybe related to the 
cell type. These are immortalized bone marrow derived macrophages that are 
grown in cell culture and split before they become confluent. They are not 
peritoneal macrophages that have been nurtured in an organic environment, and 
the long-term culture may have affected the signaling pathways. 
There is also a question of how closely bone marrow derived macrophages are 
related to peritoneal macrophages. Although a recent study shows that peritoneal 
macrophages have increased expression of proteases and acute phase factors, 
with down regulation of the production of several chemokines compared to blood 
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monocytes. There are other studies that show that the monocytes present in 
blood migrate to the tissues including the peritoneum to become resident 
macrophages 105, 106. Further work has been done by Ghosn who identified 2 
subgroups of CD11b+F4/80+ macrophages found within the peritoneal cavity 107. 
These have been termed large and small peritoneal macrophages due to size 
distinctions. Large peritoneal macrophages make up 90% of the peritoneal 
macrophage population in the naive abdomen and have higher levels of CD11b 
and F4/80. Both are able to phagocytose bacteria. Two days after LPS 
stimulation, the small macrophages become the dominate cell type, and cell 
marker data suggests that they have differentiated from blood monocytes. 
Despite the absence of evidence seen in this experiment, we can extrapolate that 
miRNA-21 affects the TLR-4 signaling pathway, though the changes to NF-κB 




INFLUENCE OF MIRNA-21 ON SURVIVAL IN 
LIPOPOLYSACCHARIDE PERITONITIS 
Introduction 
Despite having a tried and tested treatment for peritonitis and the ability to predict 
those with a higher risk of morbidity and mortality with various scoring systems, 
we still do not know why some patients are unable to contain and eliminate an 
infection, resulting in a persistence of bacteria in the peritoneum. Some 
investigators have theorized that this is due to a failure of the host immune 
response to clear the infection, and that augmentation or modulation of the 
immune response may benefit bacterial clearance in these patients. Several 
immune-modulators have been tested in clinical trials following success in a lab 
environment, however without success in a clinical setting 16, 17.  
Recent studies have shown that mice with knockdown of PDCD4 and Pelino 1 
genes have a greater survival to LPS peritonitis than their wild type counterparts 
36, 51.  These proteins affect downstream signaling of TLR-4 through MyD88 and 
NF-κB. MiRNA-21 has been shown to target both these proteins and is itself 
induced after LPS administration in macrophages 51. Based on these data we 
predicted that miRNA-21 knockout mice would have a decrease survival
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to induced peritonitis. MiRNA-21 production is stimulated through TLR-4 
signaling, so we used a model of intra-peritoneal LPS to induce peritonitis. LPS is 
considered to be an important inducer of the septic response and intra-peritoneal 
LPS is more likely to induce a hyperdynamic cardiovascular response than 





Surface temperature and weight decreased in all mice following induction of 
peritonitis with LPS (Figures 22 and 23). Failure to regain temperature and 
weight was predictive of subsequent death. The miRNA-21+/+ mice began to die 
after 24 hours, the miRNA-21-/- mice after 40 hours (Figure 24). Significantly, 
more miRNA-21-/- mice died compared with miRNA-21+/+ mice (p=0.002). 
 
Discussion 
This study was performed in a constant room temperature at 28°C, and all mice 
had reduced their body temperature following intra-peritoneal administration of 
LPS. This is typical of the response seen to induced sepsis in mice; however in 
patients the induction of fever is seen. Recent data suggest that the surroundings 
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Figure 22: Mouse Surface Temperatures after Lipopolysaccharide 
Peritonitis  
 
Surface temperature decreased in all mice following intra-peritoneal 
administration of lipopolysaccharide (LPS). The mice that died during the 
observation period remained lower than those that survived. MiRNA-21+/+ and 
miRNA-21-/-mice were included in this figure. Survivors N=5, Deaths N=21. Data 
are shown Mean ± SEM.  
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Figure 23: Mouse Weight after Lipopolysaccharide Peritonitis 
 
 
Weight decreased in all mice following intra-peritoneal administration of 
lipopolysaccharide (LPS). The mice that died during the observation period did 
not recover the weight lost. Mice that survived were regaining weight by the 





Figure 24: Survival after Lipopolysaccharide Peritonitis 
 
MiRNA-21 confers a significant survival benefit in response to 25mg/kg 










in which mice are kept impacts the temperature response 108, 109. Below a room 
temperature of 30°C, mice are already working to maintain body temperature, 
and are thus unable to generate enough heat to produce the fever response 
usually associated with sepsis. This leads to the hypothermic response seen and 
thus subsequent experiments should ideally be performed in a room at 30°C. All 
mice lost weight following induction of peritonitis. This is indicative of the 
increased metabolic demand placed on the body. Only animals that survived the 
observation period gained weight following peritonitis (Figure 23). We have used 
weight loss as a predictor of mortality in previous models of peritonitis 110.   
The knockdown of miRNA-21 confers a survival benefit in LPS peritonitis (Figure 
24). Mortality due to LPS is associated with cardiac dysfunction related to 
intravascular inflammation and thrombosis in microvasculature function 111. This 
impairment in microcirculation leads to multiple organ failure, disseminated 
intravascular coagulation (DIC) and death 112, 113. Inhibition of platelet adhesion 
through GPIb-IX binding decreases the mortality of LPS challenged mice 114. 
TNF-α activates the common pathway of coagulation, leading to thrombotic 
consequences 115. The cardiopulmonary dysfunction seen in animal models of 
sepsis can be attenuated by monoclonal TNF-α antibody 116.  
TNF-α is an important cytokine mediator of sepsis, essential to the generation of 
the innate immune response to infection. It is found in the circulation following 
administration of LPS, and when given directly mimics many of the physiological 
and laboratory features following intravenous LPS 117. However plasma levels of 
TNF-α following endotoxin are an order of magnitude higher than circulating 
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levels in sepsis 16, 118-120. If one of the downstream effects of miRNA-21 is to 
decrease circulating TNF-α levels, this correlates with the fact that the higher 
levels of TNF-α seen following LPS peritonitis are attenuated and therefore 
survival is improved in miRNA-21+/+ mice compared to miRNA-21-/-  mice. In 
miRNA-21-/- mice there would be no amelioration of the already high TNF-α levels 
seen after administration of LPS, and therefore these mice have a higher 
mortality. TNF-α blockade alone is not sufficicent to reduce mortality following 
LPS peritonitis in animals or when administered in clinical trials, and indeed 
higher doses of TNF-α blockade increases mortality 120, 121. IL-10 had been 
shown to reduce mortality in a lethal model of LPS peritonitis 87. These data 
suggests that it is not TNF-α alone, but a combination of factors by which 
miRNA-21 reduced mortality in our experiment.  
Our initial experiment focused on the TLR-4 pathway by inducing peritonitis with 
a specific ligand. However, LPS is a single protein from the outer membrane of a 
single organism (E.coli), given at a single point in time, which signals through a 
single pattern recognition receptor and triggers the innate immune response 
through the TLR-4 pathway. In reality, secondary peritoneal infection is 
polymicrobial, with entry of multiple enteric bacteria into the peritoneum, resulting 
in the continuous migration of bacteria into the vascular space, mainly through 
the subdiaphragmatic lymphatics. This results in multiple PAMPs and DAMPs 
being recognized by PRRs and the activation of multiple signaling pathways. 
Cecal Ligation and Puncture is a more representative model of peritonitis that will 
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better assess if this promising effect of miRNA-21 on mortality in peritonitis would 






INFLUENCE OF MIRNA-21 ON SURVIVAL IN CECAL LIGATION 
AND PUNCTURE PERITONITIS 
Introduction 
Our previous experiments have shown that expression of miRNA-21 confers a 
survival benefit in a lipopolysaccharide model of peritonitis. Previous studies of 
immune modulators in sepsis that have used LPS peritonitis as an experimental 
model, that showed a difference in outcome in animal studies, have not 
translated into differences in clinical studies 122. This is because LPS induced 
inflammation is not an accurate mimic of the human disease state. LPS is an 
outer membrane protein from a gram negative bacterium (often E. coli) that 
signals through a single pattern recognition receptor (TLR-4) and triggers the 
innate immune response through a single pathway. It is also given as a single 
bolus, whereas in most human infections bacteria are released and multiply in 
the bloodstream of the host more slowly over time. For these reasons we felt it 
was important to assess the influence of miRNA-21 on survival in a more 
clinically relevant model of peritonitis, CLP. The CLP model combines the entry 
of enteric bacteria into the peritoneum together with an ischemic focus and is 
thus closer to peritonitis as seen in patients. If miRNA-21 is to be a potential 
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immune modulator in a clinical setting, then it will need to show a difference in 
more clinically relevant animal models of peritonitis such as CLP. We propose 
that miRNA-21 will show a survival difference between the miRNA-21+/+ and 
miRNA-21-/- mice following CLP.  
  
Results 
Surface temperature and weight decreased in all mice following induction of 
peritonitis with CLP (Figure 25). Surface temperature improved in the mice that 
survived, though never recovered to baseline levels during the observation 
period. There was no difference in survival following induction of peritonitis with 
CLP between the miRNA-21+/+ and miRNA-21-/- mice (Figure 26).  
 
Discussion 
MiRNA-21 confers a survival benefit in LPS peritonitis but not after CLP. This is a 
result that has also been seen with other potential immune modulators 120. LPS is 
a ligand for TLR-4, and thus triggers the immune response through this single 
pathway. As miRNA-21 is induced by and acts on the TLR-4 pathway, it is 
therefore logical that we see a difference in survival between miRNA-21+/+ and 
miRNA-21-/- mice after LPS induced peritonitis. 
In contrast CLP is a combination of ischemia, foreign body reaction and 
polymicrobial infection from the enteric bacteria of the gut. This leads to a live 
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Surface temperature and weight decreased in all mice following induction of 
peritonitis with 20G cecal ligation and puncture (CLP). The mice that died during 
the observation period had lower temperatures than those that survived. MiRNA-




Figure 26: Survival after 20G Cecal Ligation and Puncture 
 
MiRNA-21 does not convey a survival benefit in response to peritonitis by 20G 
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bacterial infection with a multitude of exogenous mediators such as microbial 
DNA, lipoteichoic acid, peptidoglycan and other cell wall components which 
signal through multiple pathways such as TLR-2, TLR-6, TLR-9, NOD-like 
receptors as well as TLR-4 to initiate the immune response. LPS peritonitis is 
induced by an intra-peritoneal bolus, which induces an initial response that does 
not need to escalate over time. The infection seen after CLP involves cecal 
necrosis, with multiplying species of bacteria within the peritoneum and eventual 
bacteremia over time. The infection becomes walled off in an abscess cavity over 
the first 72 hours, and is eventually extruded through the abdominal wall if the 
animal survives 123. This ongoing contamination in CLP requires a more complex 
continued immune response. 
TNF-α is an important cytokine mediator of sepsis, essential to the generation of 
the innate immune response to infection. It is found in the circulation following 
administration of LPS, and when given directly mimics many of the physiological 
and laboratory features following intravenous LPS 117. The level of circulating 
TNF-α has a positive correlation with mortality 110, 124. Reducing the levels of 
circulating TNF-α using anti-TNF-α monoclonal antibodies in experimental animal 
models  of sepsis using LPS and gram negative bacteria, has had some success 
in decreasing mortally across a range of species 124-126. Animals unable to 
produce TNF-α in response to infection did worse than endotoxin sensitive mice, 
demonstrating that a proportional immune response is required 127. However 
plasma levels of TNF-α following LPS administration are an order of magnitude 
higher than circulating levels in polymicrobial sepsis 16, 118-120, 128. TNF-α blockade 
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has been shown to be ineffective or detrimental in mice following induction of 
peritonitis with CLP 119, 120. This is consistent with clinical trials of TNF-α 
antagonists that did not show an improved survival, and at higher doses 
increased mortality 17, 129, 130.  
MiRNA-21 decreases circulating TNF-α, and therefore will have more effect on 
the higher levels of TNF-α seen following LPS peritonitis. The attenuation of 
TNF-α that occurs in miRNA-21+/+ mice may be related to the subsequent 
improved survival.  MiRNA-21-/- mice do not have the same amelioration of the 
high TNF-α concentration seen after administration of LPS. In CLP there are 
lower levels of circulating TNF-α, and therefore the effects of miRNA-21 on TNF-
α levels will be reduced, and potentially insufficient to have an effect on mortality. 
TNF-α is not the only factor important in the pathophysiology of sepsis, as a 
reduction in TNF-α has no effect on neutrophil infiltration of the lung, as a major 
cause of mortality following CLP 120.  These data demonstrate that TNF-α is not 
the mediator of lethality in polymicrobial peritonitis, yet has a role to play with a 
multitude of other mediators. 
TLR-4 signaling produces multiple cytokines, both pro- and anti-inflammatory in 
response to stimulation with LPS, both through the NF-κB and ERK pathways. 
Following CLP, TLR-4 gene expression and protein abundance was increased in 
liver and lung compared with controls and correlates with mortality 131. 
Inflammation, tissue damage and lethality are diminished in the absence of TLR-
4 signaling 132.  
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With these data TLR-4 antagonists have been developed, which competitively 
bind to TLR-4, preventing LPS interaction, and have been shown to decrease 
pro-inflammatory cytokine release and inhibit the development of inflammation 
133-135. However the ACCESS randomized clinical trial of Eritoran®, an antagonist 
of the MD2-TLR-4 complex, did not show any significant difference when trialed 
in patients with severe sepsis 136. In contrast M62812, a molecule that inhibits 
TLR-4 signal transduction, has shown an increased survival in both D-
galactosamine-sensitized endotoxin shock model and 18G CLP model at 24 
hours 134. However increased survival over a longer time period was not 
reported. 
One group has looked further into the role of TLR-4 on different cells types. 
Using a 22G CLP model a global TLR-4 deletion and myeloid (neutrophil and 
macrophages) TLR-4 deletion had 100% mortality compared to 40% in the wild 
type mice after 7 days 137. Bacterial clearance from the circulation and 
peritoneum in these mice was significantly impaired compared to wild type. The 
failure to clear bacteria correlated with an increase in inflammatory markers, 
even in the absence of TLR-4 on myeloid cells. Efficiency of bacterial clearance 
in this model determines survival and the magnitude of the immune response, 
which are in turn determined by LPS recognition by TLR-4 on macrophages. 
TLR-4 on macrophages is therefore important for the stimulation of bacterial 
phagocytosis in polymicrobial sepsis.  
The cause of mortality related to LPS peritonitis differs from that seen after CLP 
90. LPS mortality is associated with cardiac dysfunction and related to 
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intravascular inflammation and thrombosis in the microvasculature 111. This 
impairment in the microcirculation leads to multiple organ failure, disseminated 
intravascular coagulation (DIC) and death 112, 113. TNF-α activates the common 
pathway of coagulation, leading to thrombotic consequences 115. The 
cardiopulmonary dysfunction seen in animal models of sepsis can be attenuated 
by monoclonal TNF-α antibody 116.Suppression of LPS-induced up-regulation of 
inflammatory cytokines, by TLR-4 signal transduction inhibitor M62812, also led 
to suppression of pro-coagulant activity in peripheral mononuclear cells 134. Up-
regulation of pro-coagulant activity in leukocytes and down-regulation of 
anticoagulant activity in endothelial cells leads to microthrombosis in several 
organs, leading to multiple organ failure. Inhibition of platelet adhesion through 
GPIb-IX binding also decreases the mortality of LPS challenged mice 114.  
After CLP animals develop an initial hyper dynamic cardiovascular response, 
similar to that seen in patients with increased cardiac output and decreased 
systemic vascular resistance 90. This develops into systemic bacteraemic 
infection and sepsis, which progressively become cardiovascular collapse due to 
septic shock and death days after the initial insult, similar to the condition seen in 
peritonitis patients who die from multiple organ failure days after the onset of 
infection. CLP using a 16G double puncture technique leads to a significant 
cardiac dysfunction, shown by a decreased ejection fraction by 25.7% 138. There 
is also a component of lung injury due to neutrophil infiltration 139.  Innate 
immunity also participates in polymicrobial sepsis-induced acute kidney injury 
through the MyD88 pathway, by leading to an increased migration of neutrophils 
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to the kidney, increased production of pro-inflammatory cytokines, vascular 
permeability, hypoxia and apoptosis of tubular cells 140. TLR-4-/- mice had 
decreased renal injury at 24 hours with a diminished systemic cytokine response 
following 23G CLP 140. CLP and LPS both enhance thrombotic occlusion in wild-
type mice 141. LPS, but not CLP, increased plasma VWF antigen relative to 
controls. CLP alternatively enhanced thrombosis in TLR-4 and VWF-deficient 
strains. As miRNA-21 has not been shown to have a regulatory role in other 
immune signaling pathways, the redundancy present from the multiple pathways 
stimulated in CLP may minimize the effects of miRNA-21 in this peritonitis model. 
These experiments used whole body knockout mice to model an absence of 
miRNA-21. As these mice survived to 12 weeks and beyond we know that 
miRNA-21 is not essential for animal survival. We do not know what adaptions 
have occurred within the mouse, specifically in the immune system in order to 
compensate for the missing miRNA-21, though there were no significant changes 
in hemopoetic cells populations seen in the blood, peritoneum or bone marrow 
on flow cytometry (data not shown). Creation of a model that has inducible 
knockdown of miRNA-21 in only the macrophage population would be ideal to 
truly see the effect of macrophage miRNA-21 in these models of peritonitis. A 
closer model would be to transplant bone marrow from miRNA-21-/- mice into 
miRNA-21+/+ mice, as then the subsequent miRNA-21 knockdown would be 
confined to only the hematological cells. However, this would still allow for 
adaptations to occur within the immune system. 
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Although mortality is a definitive end-point most patients survive an episode of 
peritonitis with modern therapy. MiRNA-21 may still ameliorate the severity of 
infection without affecting mortality rate. In patients, decreasing the need for 
organ support and intensive care would be a significant step forward in improving 






MIRNA-21 EXPRESSION IN PERITONEAL MACROPHAGES 
FOLLOWING CECAL LIGATION AND PUNCTURE PERITONITIS 
Introduction 
Cecal ligation and puncture is among the most representative models of human 
peritonitis. Multiple pathways are stimulated by the polymicrobial infection from 
enteric bacteria. These pathways stimulate cell activation and trigger secondary 
cascades, resulting in cytokine and chemokine release. MiRNA-21 regulates the 
TLR-4 signaling cascade, one of many that are activated by polymicrobial intra-
abdominal infection. We saw no difference in survival between miRNA-21+/+ and 
miRNA-21-/- mice following 20G CLP. We propose, based on these data, that 
despite the absence of a difference in survival, we will see a difference in the 






MiRNA-21-/- was confirmed by RT-qPCR. In miRNA-21+/+ mice miRNA-21 
expression was initially down-regulated in the F4/80+ peritoneal macrophage 
population at 6 and 24 hours following CLP (Figure 27). At 48 hours the 
expression was up-regulated by 500 fold but with a wide range of variation. 
Cell Populations 
MiRNA-21+/+ and miRNA-21-/- mice had no difference in the number of peritoneal 
exudate cells harvested from the peritoneum at 6, 24 or 48 hours after 20G CLP 
(Figure 28). The number of macrophages isolated was not different between the 
groups, nor the macrophage population as a percentage of the total number of 
PEC cells (Figure 29).  
Effect of miRNA-21on Peritoneal Cytokines levels 
Following 20G CLP TNF-α was higher in the peritoneal lavage media from 
miRNA-21+/+ mice at 6 hours (p=0.009), but no different at 24 and 48 hours 
(Figure 30). IL-6 concentrations peaked at 6 hours after CLP, but was no 
different in the peritoneum between miRNA-21+/+ and miRNA-21-/- mice (Figure 
31). Similarly IL-10 levels were maximally elevated at 6 hours, with the same 





Figure 27: Peritoneal Macrophage MiRNA-21 Expression after Cecal 
Ligation and Puncture 
 
Peritoneal macrophage miRNA-21 expression after 20G cecal ligation and 









Figure 28: Peritoneal Exudate Cell counts after Cecal Ligation and Puncture 
 
There is no difference in the number of peritoneal exudate cells between miRNA-
21+/+ and miRNA-21-/-mice following cecal ligation and puncture (CLP). N=7-8. 








Figure 29: Peritoneal Macrophages after Cecal Ligation and Puncture 
 
 
A) There is no difference in the number of peritoneal macrophages between 
miRNA-21+/+ and miRNA-21-/-mice, not B) the percentage of the total peritoneal 
population following cecal ligation and puncture (CLP). N=7-8. Data are shown 
Mean ± SEM.  
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Figure 30: Peritoneal TNF-α after Cecal Ligation and Puncture 
 
There is no difference in the peritoneal TNF-α levels between miRNA-21+/+ and 
miRNA-21-/-mice following cecal ligation and puncture (CLP). N=7-8. Data are 







Figure 31: Peritoneal IL-6 after Cecal Ligation and Puncture 
 
There is no difference in the peritoneal IL-6 between miRNA-21+/+ and miRNA-
21-/-mice following cecal ligation and puncture (CLP). N=7-8. Data are shown 
Mean ± SEM.  
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Figure 32: Peritoneal IL-10 after Cecal Ligation and Puncture 
 
There is no difference in the peritoneal IL-10 between miRNA-21+/+ and miRNA-
21-/-mice following cecal ligation and puncture (CLP). N=7-8. Data are shown 











We have shown that after CLP there is an initial down-regulation in MiRNA-21 
expression followed by a delayed up-regulation at 48 hours. This is in direct 
contrast to LPS, which shows a linear up-regulation of miRNA-21 after 
stimulation. This early down-regulation in the macrophages at 6 hours may be 
due to a delay in the stimulation of TLR-4 by bacteria migrating from the lumen of 
the bowel into the peritoneum. However this would not explain the data from the 
24 hour time point.  
Exosomes are 40-10nm membrane vesicles that are secreted by cells as part of 
cell-cell communication. Recent studies have shown that miRNA-21 is secreted 
in exosomes into peritoneal fluid at higher levels in ovarian serous carcinoma 
than normal controls 54. Exosomal miRNA-21 expression has also been up-
regulated in serum in esophageal cancer and cervicovaginal lavage in cervical 
cancer 142, 143. If intra-cellular macrophage miRNA-21 was secreted into the 
peritoneum following CLP, this may account for the decreased expression seen 
within the cells at 6 and 24 hours.  
We observed no difference between miRNA-21+/+ and miRNA-21-/- mice in PEC 
cell count, total macrophage count or macrophages as a percentage of the total 
number of PEC cells. TNF-α was higher in the peritoneal lavage media from 
miRNA-21+/+ mice at 6 hours. All other cytokines were similar regardless of the 
presence or absence of miRNA-21. 
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These data partially explain why there was no difference in survival observed 
between miRNA-21+/+ and miRNA-21-/- mice following induction of peritonitis with 
20G CLP. Collectively our data suggest that TLR-4 signaling has a definite role to 
play in the innate immune response to peritonitis, though the redundancy of 
multiple pathways stimulated in following induction of peritonitis with CLP may 
minimize the effects of miRNA-21 in this model. 
Although miRNA-21 did not show a survival benefit, we believe that there may 
still be a therapeutic role for miRNA-21 in a clinical setting. Further experiments 
are required to ascertain the presence and pattern of exosomal or free miRNA-21 
in peritoneal fluid, both in the normal and infected abdomen. Examination of 
abdominal washings or drain fluid in post-operative surgical patients, will likely 
yield novel data about the role of miRNA-21 in peritonitis. Although knockout of 
miRNA-21 was not effective in changing survival, there may be a role for 
increasing miRNA-21 expression within the peritoneum to affect the severity of 









CONCLUSIONS AND OVERVIEW 
The early innate immune response to invading microbes during peritonitis is 
largely orchestrated by the peritoneal macrophage. These cells have three basic 
functions: phagocytosis, antigen presentation, and protein secretion. 
Macrophages have been classed into two phenotypes - M1, the classical or pro-
inflammatory macrophage that produces TNF-α, IL-1, IL-6, nitric oxide and has 
strong microbial activity, and M2 or alternatively activated macrophages that 
produce IL-10, Arginase-1 and Mrc1 (CD206) and are involved in preventing 
excessive injury in the host tissue remodeling 144, 145. Macrophages can be 
converted from one phenotype into another. The key transcription factors 
involved in macrophage polarization are STATs, NF-κB, and camp-responsive 
element-binding protein (CREB). Therapeutic targeting to change the polarization 
of macrophages is still in the primordial phase of development, but the 
microenvironment and anatomical location of the cells are important 145, 146. We 
have shown that miRNA-21 modulates the cytokine output of peritoneal 
macrophages, from a pro- to anti-inflammatory profile, suggesting that miRNA-21 
is involved in macrophage polarization. The reduction in TNF-α and IL-6 together 
with the increase observed in IL-10 production in response to LPS with increased 
miRNA-21 may indicate a role in the transition of macrophages to a M2
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alternative activation state. Further characterization of whether there is any 
difference in the M2 expressed genes such as Arginase-1, chitinase 3-like 3 
(Ym1), and Mrc1 (CD206) between miRNA-21-/- and miRNA-21+/+ cells should 
yield novel data to clarify the active mechanisms involved in the transition of the 
early innate immune response to peritonitis.   
Indeed, a study of microbial tolerance has shown that a LPS-tolerant state leads 
to a M2 polarized phenotype in macrophages 104, and the NF-κB p50 subunit is 
the key regulator in this transformation. Our experiments focused on the p65 
subunit, and this may contribute to why differences in the activation of NF-κB 
were not observed in these experiments. 
Recent reports in the literature have postulated an early/acute hyper-
inflammatory and a late/chronic hypo-inflammatory phase in response to sepsis 
84, 113, 147, 148. This immunosuppression phase in late sepsis leads to mortality 
from persisting primary infection or an opportunistic new infection, otherwise 
known as the two hit model. Some data suggest that altered myeloid maturation 
or differentiation may be important. Adoptive transfer of CD34+ hematopoietic 
stem-progenitor cells after CLP improved survival by 65%. Cell transfer resulted 
in no change in the early hyper-inflammatory response, but corrected the later 
immunosuppression, increasing circulating pro-inflammatory cytokines, 
enhancing phagocytic activity and clearing bacterial peritonitis. It is likely that 
these new cells differentiated into competent immune cells in the blood and 
tissue, reversing or replacing hyporesponsive endotoxin-tolerant cells in the 
peritoneum 149. We have no current data about the role of miRNA-21 in this late 
100 
 
stage of sepsis, though theoretically if it is still active, then inhibition of miRNA-21 
to change to a more pro-inflammatory response maybe potentially beneficial. 
There are numerous limitations on this work. The isolation process may have 
activated macrophages, though we tried to counteract any effects by using a 
gentle process and resting the cells for 24 hours prior to use to alleviate some of 
these effects on subsequent stimulation. Bone marrow derived macrophage cell 
lines were used to evaluate the absence of miRNA-21, however these 
macrophages are an immortalized cell line, which are not primary peritoneal 
macrophages. These cells are likely to be phenotypically or genetically different 
from primary peritoneal macrophages and therefore are only able to approximate 
what is occurring in the peritoneum. The evaluation of the individual cell type 
responses in vitro also need to be related to what in occurring in vivo as cells do 
not respond alone, multiple cells types communicate and respond to infectious 
stimuli together. 
In conclusion, we found that miRNA-21 expression increases in macrophages 
after LPS stimulation. MiRNA-21 decreases TNF-α and IL-6 production, while 
increasing IL-10. The mechanism by which the expression of these cytokines 
was modulated is not clear from these experiments. PDCD4 has emerged as the 
most likely target protein to be effecting the cytokine modulation, though NF-κB 
activation was not different.  
MiRNA-21 is beneficial in survival from an LPS model of peritonitis but not after 
CLP, as it does not have sufficient power to change the peritoneal cytokine 
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profile that is associated with mortality. Although miRNA-21 did not change 
survival after CLP, there may still be a therapeutic role in peritonitis that warrants 
further investigation. If miRNA-21 can ameliorate the severity of infectious 
sequelae, that would be clinically beneficial. The healthcare costs involved with 
intensive care and multi-organ support are significant. Reducing admission to or 
length of stay in the intensive care unit would positively impact the care of 
patients with peritonitis.  
MiRNA-21 is present in plasma and peritoneal fluid 50, 54, 150. There are currently 
no data on the presence and pattern of exosomal or free miRNA-21 in peritoneal 
fluid, in either the normal or infected abdomen. Isolation of miRNA-21 from peri-
operative abdominal washings undergoing abscess drainage or drain fluid in 
post-operative surgical patients would improve our understanding of the course 
of miRNA-21 secretion in response to clinical peritonitis. Future animal 
experiments could determine if the addition of exogenous miRNA-21 to the 
peritoneum after CLP is able to modulate the local immune response in vivo.   
We hypothesized that the outcome of peritonitis can be modulated by miRNA-21 
through down regulation of NF-κB signaling that affects macrophage cytokine 
release, to diminish local inflammation. These findings demonstrate that although 
miRNA-21 is beneficial in modulating the macrophage response to LPS, the 
effect is buried in the multiple pathways activated after the clinically more 
relevant model of CLP. The improved understanding of the anti-inflammatory 
effects of miRNA-21 in macrophage response to peritonitis may result in a 
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APACHE Acute Physiology and Chronic Health Evaluation 
CLP Cecal Ligation and Puncture; peritonitis model   
DIC Disseminated Intravascular Coagulation  
ELISA Enzyme Linked Immunosorbent Assay 
PEC Peritoneal Exudate Cells 
 
Cell Biology 
CREB  CAMP-responsive Element-Binding Protein 
ceRNA Competing Endogenous RNA 
cDNA  Complementary DNA 
mRNA Messenger RNA; longer, single stranded RNA; template for protein 
translation  
miRNA MicroRNA; short single stranded RNA  
Peli1  Pelino1; target of miRNA-21 
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PDCD4 Programmed Cell Death Protein 4; target of miRNA-21 
RAW264.7 Mouse macrophage cell line 
RISC  RNA-Induced Silencing Complex 
siRNA  Silencing RNA; prevents translation of target mRNA into protein 
SPRY  Sprouty; target of miRNA-21 
 
Immunology 
CD206 Cluster of Differentiation 206; marker of M2 macrophages 
DAMP  Damage Associated Molecular Protein 
IL-6  Interleukin-6; pro-inflammatory cytokine 
IL-10  Interleukin-10; anti-inflammatory cytokine  
LPS Lipopolysaccharide; part of the outer membrane of gram-negative 
bacteria; a DAMP 
PAMP Pathogen Associated Molecular Protein; bacterial or viral peptide 
recognized by the immune system 
PRR Pattern Recognition Receptor; receptors that recognize DAMPs 
and PAMPs   
TLR  Toll-Like Receptor; a PRR  
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TNF-α  Tumor Necrosis Factor-α; pro-inflammatory cytokine 
 
Pathway 
ELK1 part of the MAPK pathway 
ERK Extracellular Signal Related Kinase; part of the MAPK pathway and 
important for IL-10 production  
IKK Inhibitory Kappa Kinase; activator of NF-κB IκB  
IκB  Inhibitory kappa protein Beta  
IRAK IL-1 Receptor Associated Kinase; central signaling protein of the 
TLR-4 pathway 
JNK c-Jun N-terminal Kinase 
MAPK Mitogen Activated Protein Kinases pathway; part of the TLR-4 
signaling pathway 
MyD88 Myeloid Differentiation Primary Response Gene 88; central 
signaling protein of TLR-4 
NF-κB Nuclear Factor Kappa Beta; transcription factor of TLR-4 signaling 
RIP1 TRIF-signaling adaptor kinase; interacts with Peli1 




TRAM TRIF-related Adapter Molecule 
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Feb – Aug 2012 
Using a novel model of chronic peritonitis we looked at microRNA expression in 
the peritoneum in predicted survivors compared to predicted deaths. 
 
MicroRNA Expression in Microbial Tolerance Oct 2011 – Feb 2012 
Using a novel model of chronic peritonitis we looked at microRNA expression in 
the peritoneum of mice following the induction of microbial tolerance. 
 
Analysis of Centrosomal Proteins in Chronic Lymphocytic Leukaemia  
BSc project       March - May 2004 
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Expression of TACC3 centrosomal protein in patients with chronic lymphocytic 
leukaemia compared to other white cell diseases. 
 
Skills in Molecular Biology 
Cell Culture  
Magnetic Bead Isolation 
RNA Isolation  
Polymerase Chain Reaction for messenger and microRNA. 
Protein quantification 
Enzyme-linked Immunosorbent Assay (ELISA) 
Western Blot 
Immunofluorescence 
Transfection of microRNA into peritoneal macrophages 
Animal Handling and Injections 
Caecal Ligation and Puncture 
Harvest of Peritoneal Cells, Blood and Tissues (Lung, Liver, Cardiac) 





Supracondylar Fractures of the Humerus in Children  Jul  2011  
Role: Audit design, data analysis and write up.  
Loop closed: No. 
Standards: Guidelines from O’Hara et al J Bone Joint Surg [Br] 2000. 
Performed: North Devon District Hospital, Barnstaple, Devon. 
Results: Presented at Orthopaedic teaching. 
 
Massive Blood Transfusion Protocol     Feb 2011 
Role: Audit design, data analysis and write up.  
Loop closed: Yes. 
Standards: Local Guidelines  
Performed: North Devon District Hospital, Barnstaple, Devon. 
Results: Presented at Anaesthetic & Surgical and Medical Clinical Governance 
meetings.  
 
Fibrinolysis in acute myocardial infarction    Dec 2008 
Role: Audit design, data analysis and write up.  
Loop closed: Yes, July 2009, following my departure. 
Standards: Local Network Guidelines  
Performed: Lismore Base Hospital, Lismore, New South Wales, Australia. 
Results: Presented at Emergency Department and Registrar teaching.  
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Thromboprophylaxis in high risk patients    Jun 2008 
Role: Data collection, analysis and write up.  
Loop closed: Yes, Dec 2008, following my departure. 
Standards: Department of Health Guidelines  
Performed: Poole General Hospital, Poole, Dorset. 
Results: Presented at local clinical governance meeting.  
 
Clinical Experience: 
I am happy running general surgical on-calls including vascular surgery. I have 
experience looking after patients in outpatient clinics, and on the wards. I have 
experience preparing the patient for surgery, directing peri-operative care in 
theatre, and managing them on the ward, including recognising and treating 
common post-operative complications. 
I am happy diagnosing and managing simple cutaneous abscesses, appendicitis, 
peritonitis, gallstone disease, including deciding for surgical intervention, and can 
perform incision and drainage of abscess and appendicectomies, laparoscopic 
and open with supervision. I can also perform laparoscopic cholecystectomies 
with direction. 
I have experience running trauma calls in a level 2 trauma centre. 
My 6 months spent working as medical registrar in Australia has given me 
experience running medical on-calls, and performing medical reviews on surgical 
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and orthopaedic patients, recognising and managing medical problems in 
surgical patients.  
 
Continuing Medical Education (CME): 
Attendance at Grand Rounds and Price Institute of Surgical Research Seminars 
         Jan 2012-present 
Principles of Clinical and Translational Research   Aug 2012 
Teach the Teachers        Jul 2011 
CCrISP          Jun  2011 
Introduction to Medical Education      Feb  2011 
ATLS          Jun  2010 
Basic Surgical Skills       Mar  2008 
M27 Course (Coloproctology)      Nov  2007 
Introduction to ENT         Sept  2007 
Advanced Life Support        Nov  2006 








I have experience of teaching medical students and more junior doctors in a 
clinical environment, making use of available patients to teach about history 
taking, presentation and examination techniques. I have also taught medical and 
work experience students in a theatre environment, educating about the surgical 
experience and surgical technique. 
I have planned formal teaching sessions for Foundation Doctors, using both 
lecture based, and more interactive methods. 
I have used laparoscopic training devices with colleagues to show and 
encourage work experience students about careers in medicine and surgery as 
part of a wider curriculum. 
I have aided colleagues and nursing staff with skills such as ECG and arterial 
blood gas interpretation, intravenous cannulation, catheterisation and suturing by 
demonstrating and then supervising the procedures.  
As part of the BBC 999 Roadshows I have taught basic resuscitation skills to 
members of the general public. 
I undertook modules on teaching and learning as part of my regional F2 study 
days at Bournemouth University. I have also undertaken courses on medical 
education and teaching specific to medicine in order to improve my teaching 
skills. This has given me specific tips and practice planning teaching session as 
well as dealing with different and difficult situations. 
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I also enjoy educating patients about their diseases and prognosis in language 
that they can understand, taking time to answer their questions and drawing 
diagrams to aid comprehension. 
In my 2 years as Research Fellow in the Price Institute of Surgical Research I 
have taught many undergraduate and medical students research techniques, 
analysis of data and how to construct and present research data. 
 
Management: 
Research Fellow        Oct 2011 
As the research fellow within the Veterans Affairs Surgical Research Laboratory, 
I organise and plan experiments. I order needed reagents and animals, ensure 
the laboratory meets all federal and national safety requirements and train and 
supervise my undergraduate and medical student laboratory assistants.  
I have collaborated with multiple principle investigators across research 
specialities and co-ordinated research plans for projects using knockout mice. 
 
VTE Committee Member       Nov 2009  
Junior Doctor Representative on North Devon District Hospital Venous 
Thromboembolism Committee, introducing new VTE risk assessment forms 
throughout the trust, and their integration into new drug charts. 
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Rota Co-ordinator         Oct 2008 
Involved in developing new surgical rota with change of staffing levels. Managed 
Surgical Junior rota and annual leave. 
 
Organised ALS courses for all F1s at Poole.    Nov 2007 
 
Regatta Director for Bournemouth Lifeguard Corps   Jul 2007 
Organised the Bournemouth Lifeguards Regatta, a two day National Beach 
Lifeguarding Competition, with 13 teams of six people from around the country 
competing in a variety of events. The events use many lifeguard skills including 
incidents (in the sea and on land), first aid, reel & line, rope throwing, knots, iron 
man, canoeing, torpedo relay and other unique events.   The competition is 
organised in such a way that every member of the team is involved throughout 
the weekend and every member of the team should be proficient in the wide 








Surgical Infection Society – North America, Baltimore, MD   Apr 2014 
Southeastern Surgical Congress, Savannah, GA   Feb 2014 
American College of Surgeons, Washington DC   Oct 2013 
Surgical Infection Society – Europe, Prague, Czech Republic  May 2013 
Association of Veterans Affairs Surgeons, Milwaukee, WI   Apr 2013 
Surgical Infection Society – North America, Las Vegas, NV   Apr 2013 
Southeastern Surgical Congress, Jacksonville, FL   Feb 2013 
Academic Surgical Congress, New Orleans, LA   Feb 2013 
Association of Veterans Affairs Surgeons, Miami Beach, FL  Apr 2012 
Southeastern Surgical Congress, Birmingham, AL   Feb 2012 




Surgical Infection Society – North America    Jun 2013 
Women In Surgery (WinS)       Aug 2010 





I am comfortable using Microsoft Office, and have a GSCE (short Course) in 
Information Technology. I am familiar with several variations on PACS and 
pathology results systems. I regularly use the internet to access electronic 
journals and online information. I have experience using Sigma plot to statistically 
analyse data and create graphs to aid comprehension. 
 
Extra-Curricular: 
I enjoy Salsa and Swing dancing, climbing both indoors and outdoor, especially 
Winspit, on the Isle of Purbeck, Dorset. I learnt to surf when living in Byron Bay, 
Australia, a pastime I was able to continue whilst living in North Devon. I also 
enjoy scuba diving, first dipping my feet off the coast of Kenya, and going on to 
become a qualified PADI open water in Thailand. I have since dived in the UK, 




I am working towards becoming a Consultant General Surgeon with an interest in 
both bench and clinical research in the field of peritonitis. I have an interest in 
upper gastrointestinal surgery, with laparoscopic surgery and hernias. My 
elective in Ghana has also given me the wish to work in Africa in the future, when 
I have an appropriate surgical skill base. 
 
 
 
